Vacuum assisted wound dressing

Information

  • Patent Grant
  • 11701266
  • Patent Number
    11,701,266
  • Date Filed
    Monday, June 28, 2021
    3 years ago
  • Date Issued
    Tuesday, July 18, 2023
    a year ago
Abstract
Apparatus for the application of topical negative pressure therapy to a wound site is described, the apparatus comprising: a wound contacting element for retaining wound exudate fluid therein; a wound covering element that provides a substantially airtight seal over the wound contacting element and wound site; a vacuum connection tube connecting a wound cavity to a vacuum source; and a vacuum source connected to a distal end of the vacuum connection tube.
Description
BACKGROUND OF THE INVENTION
Field of the Invention

The present invention relates to a topical negative pressure (TNP) assisted wound dressing particularly, though not exclusively, for the treatment of wounds of relatively low area and/or relatively low volume.


The subject of this invention is an apparatus for the management of small to medium sized wounds that utilises a vacuum source but manages wound exudate in a traditional manner by utilising an absorbent self-cohesive material in the wound cavity. No fluid is exported from the locality of the wound cavity other than by local evaporation. In this manner, an extremely portable system, of minimal inconvenience to the wearer, can be generated.


Background to the Invention

TNP therapy has enjoyed relatively recent commercial success. WO9605873 and its family members describes a portable TNP therapy apparatus. The apparatus described mechanically supports tissue in the vicinity of the wound site and tissue mechanics and the rate of exudation from such sites requires a system such as that described in WO9605873 or as described in patents such as GB2378392 and WO2005/082435 which have remote waste receptacles to which wound exudate fluid is aspirated in order to cope with the volume of fluids generated in a relatively short time, less than that period in which a dressing would normally be left in place. However, for wounds of surface area below approximately 200 cm2 or internal volumes below about 1000 cm3 these solutions may not be the most appropriate since exudate volumes and exudate rates from these wounds may be managed by more traditional wound dressings, requiring dressing change every 3-7 days. The relatively small dimensions of such wounds do not make them attractive for the traditional TNP therapies disclosed in the prior art; these devices typically including a remote vacuum source, fluid transfer lumen and remote fluid collection receptacle, control and power source and are of dimensions and weight exceeding those convenient or discrete for the patient to carry.


The general principles of TNP apparatus described in the prior art comprise a fluid-permeable wound cavity filling element, a dressing for covering the wound and providing a reasonably air-tight seal around the wound, a drainage tube connecting the wound site and cavity filling element to the vacuum source via a fluid collection canister. The precise nature of the wound filling element has been the subject of much invention in this field. The mode of action of the apparatus is the application of negative pressure to the wound cavity, causing compression of the wound cavity filler and expansion of the surrounding tissue into the wound cavity. Wound exudate is drawn from the surrounding tissue, through the still porous cavity filler, along the drainage tube and into the remote collection receptacle. An important feature of the prior art is the ability of the wound cavity filler to remain sufficiently porous, when compressed under negative pressure, to allow fluid transport from the tissue to the drainage or aspirant tube. Porosity can be facilitated at the molecular level, for example in a hydrogel, or at the microscopic level, for example in a hydrocellular foam. To facilitate fluid flow, a hydrophobic filling has been deemed particularly desirable by workers in the field and absorbent fillers as being particularly undesirable due to their hindering fluid transport.


In contrast to the principles of TNP therapy, the general principle of traditional wound dressings is the localisation of wound exudate at the locality of the wound, either within the wound cavity or in close proximity to the surface. For this purpose, extremely absorbent materials are desirable that retard the free flow of fluid, preferably absorbing the fluid and localising it. Aquacel (trade mark) made by ConvaTec Ltd is an example of a non-woven dressing that absorbs substantial quantities of fluid and effectively locks it in the dressing. Allevyn (trade mark) made by Smith & Nephew Ltd is an example of a foam dressing that absorbs substantial quantities of fluid while allowing rapid transpiration through a high moisture vapour permeable top-film.


Summary of Some Exemplifying Embodiments

In summary, the prior art deals exclusively with vacuum assisted fluid transport away from the site of the wound. A very broad range of wound cavity filling and contacting elements have been described and exemplified in the prior art, including materials commonly used in traditional wound care dressings. Without exception in these cases, the cavity filling and wound contacting elements act as a conduit for the transport of fluid from the wound per se to a remote collection canister via an aspirant tube connected to a vacuum source.


An object of the present invention is to overcome or reduce the limitations of the prior art for the management of wounds of low surface area, particularly those below approximately 200 cm2 or internal volumes below 1000 cm3, while not resorting to the exclusive use of traditional absorbent dressings. A further object of the present invention is to overcome or minimise the problem of vacuum device portability.


According to a first aspect of the present invention there is provided apparatus for the application of topical negative pressure therapy to a wound site, the apparatus comprising: a wound contacting element for retaining wound exudate fluid therein; a wound covering element that provides a substantially airtight seal over the wound contacting element and wound site; a vacuum connection tube connecting the wound contacting element to a vacuum source; and a vacuum source connected to a distal end of the vacuum connection tube.


The wound contacting element essentially blocks liquid transport beyond itself under pressures between atmospheric pressure and 200 mmHg below atmospheric pressure. Preferably, the wound contacting element material blocks liquid transport beyond itself at pressures of up to 250 mmHg below atmospheric pressure.


This invention concerns apparatus including a dressing for the management of wounds. In contrast to current therapies and prior art in the field of TNP therapy, the invention provides a system that, while exposing the wound to the many benefits of TNP, does not allow the export of wound fluid from the confines of the wound cavity. The apparatus relies upon a wound contacting element that does not allow the transport of fluid beyond itself under the range of negative pressures being applied to the wound.


A particular advantage of the apparatus according to the present invention is that confinement of wound fluid to the immediate vicinity of the wound enables the provision of an extremely small and light and consequently highly portable vacuum source and a convenient simple coupling and decoupling means of the vacuum source to the wound site dressing and which overcome significant limitations in the usability and portability of prior art apparatus.


In the present specification the term ‘wound contacting element’ means the portion of the apparatus/dressing filling the wound cavity or covering the wound. The nature of the wound contacting element is not restricted, provided that its composition or structure is able to essentially block the flow of exudate away from itself under the pressure range specified above.


For example, the wound contacting element may include a liquid-triggered valve that closes when it becomes in contact with a liquid. Such a valve may be situated proximate to the vacuum tube connection point at the wound covering element. Thus, when contacted by liquid the valve closes and no liquid is transported by the vacuum tube. The valve may be an electromechanical valve or a smart valve comprised of a water-absorbent material that expands to close within a constriction upon contact with liquid. The water-absorbent material may be placed within a restricted aperture within the valve. The wound contacting element positioned between such a valve and the wound may be absorbent or non-absorbent but may preferably be absorbent. The filling, in this embodiment, may be any medically-suitable composition such as, for example, a gauze, a foam, a woven, a non-woven, knit or moulded material.


Alternatively, the wound contacting element may comprise entirely, or in part, a suitable material structured such that it can absorb wound exudate but does not allow transmission of this fluid to the vacuum tube. This configuration is defined by two parameters: the aperture of the exit(s) from the material constituting the wound contacting element and the mechanical integrity of the material when wet. For example, an absorbent material that becomes laden with exudate must not itself be displaced along the vacuum connection tube. This is a particular problem with particulate or fibrous so-called superabsorbent materials, for they can pass, even when fully saturated with fluid, through very small apertures of a size below which vacuum levels cannot be efficiently maintained. In effect this means that the narrower the tube transmitting the vacuum, the greater the loss in vacuum pressure with distance from the vacuum source, which loss in negative pressure is negligible for macroscopic bores but can be significant as bores reduce below 1 mm diameter. To overcome these problems, an absorbent material with substantially enhanced self-cohesive properties compared to those currently available is described in our co-pending patent application GB0719065.5 of common ownership herewith.


When an absorbent material is included in the wound contacting element, the absorbent material not necessarily acting as a fluid transport blocking element, the material may preferably be capable of absorbing more than 5-times its own weight in fluid, more preferably more than 10-times its own weight in fluid and more preferably still more that 15-times its own weight in fluid. Such high w/w fluid absorbency may be desirable so that the wound can be initially dressed with a low weight material thereby reducing stress on the wound and the patient.


One group of materials particularly suited for this purpose are so-called superabsorbent materials, for example, those based on polycationic or polyanionic polymers. Superabsorbent polyanionic polymers include polyacrylic acid salts and polyacid derivatives of polysaccharides, such as carboxyalkylcellulose, or structural derivatives. Preferably, when the material is polyanionic, it may be a polyacrylic acid salt or derivative or carboxymethylcellulose or derivative. Preferably, when the material is polycationic, it may be chitosan-based, more preferably a carboxyalkylchitosan or derivative, even more preferably carboxymethylchitosan.


One particularly preferred material is a superabsorbent material capable of self-coalescence upon fluid absorption (see our GB0719065.7 the content of which is included herein by reference). These materials are able to effectively block the transport of liquid beyond their boundaries and also do not themselves flow or disaggregate under the influence of negative pressure or at the levels of externally applied physical stresses resulting from the negative pressure within a wound cavity.


A preferred material attribute may be the ability to achieve rapid haemostasis in the event of bleeding in the wound site.


A further preferred material attribute may be the ability to kill pathogens, such as bacteria or fungi, which come into contact with it. Preferably the material is inherently antimicrobial.


Carboxyalkylchitosan-based materials are suitably both haemostatic and antimicrobial.


The wound contacting element material can be provided in any form suitable to enable fluid ingress and absorption but to block the flow of fluid away from the wound contacting element. Suitable designs include dispersions of superabsorbent particles within a network of wicking fibres (as utilised in diapers, for example) or reticulated or discontinuous material comprising the superabsorbent material, such as open celled foams, knits, laminates, woven or non-woven materials. Preferably, the material may be in the form of a non-woven sheet for application to largely two-dimensional wounds or non-woven balls for application to largely three-dimensional wound cavities.


The wound covering element may be any material substantially impermeable to the flow of liquid, but may or may not be substantially permeable to the transmission of water vapour. The wound covering element is preferably a highly conformable transparent material which may optionally be coated with, or be manufactured such that, the side contacting the wound contact element and the patient's skin may be considered adhesive to the skin. Here, adhesive is taken to mean able to stay in place in the absence of negative pressure. Suitable materials for the manufacture of a highly conformable transparent wound covering include polyurethanes, polyolefins, polyacrylates, silicone-based polymers or composites comprising any combination of these materials.


The wound covering element may be a traditional wound dressing, for example composed of an absorbent foam, for example, Allevyn (trade mark) made by Smith & Nephew Medical Limited or non-absorbent film such as Tegaderm (trade mark) made by 3M Inc.


The wound covering element may be optionally provided with a means of connecting the vacuum connection tube with the wound covering element by, for example, a central or radial aperture or apertures in the wound covering element. The wound contacting element may be connected, via the wound covering element, to the vacuum connection tube by any means known to the skilled person including luer fittings such as commercially available valves and ports, magnetic couplings or adhesive sheet or tape. The connection of the vacuum tube to the wound covering element may preferably be achieved via a non-adhesive elastomeric cup positioned at the end of the vacuum connection tube and a pressure-sensitive valve positioned in the wound covering element itself. The pressure-sensitive valve may open when a pressure differential of a specified magnitude exists over its two surfaces such as between 5 and 200 mmHg, for example. The material comprising the elastomeric cup and pressure-sensitive valve may preferably be a silicone-based material. It is desirable that the coupling system is suitable for repeated coupling and uncoupling, as convenient for the patient.


Optionally, these coupling elements may be impregnated or coated with antimicrobial materials including, but not restricted to, antibiotics, silver compounds or materials, iodine-based formulations, polyhexamethylene biguanide, triclosan or chlorhexidine. Preferably, the elements may be coated with silver clusters.


The vacuum connection tube may be any of appropriate mechanical properties and bore for the transmission of negative pressure from the vacuum source to the wound contacting element. However, dependent upon the configuration of the wound contacting element, the bore of the tube may be such that it is incapable of transmitting dry or hydrated components of the wound contacting element. The tubing may be as conformable and light weight as possible and may be coiled or linear. The tubing may be single or multi-lumen, or a combination of lumens, and may optionally split and or rejoin to form separate tubular elements for the management of a single wound site or multiple wound sites. The tubing may be opaque or transparent.


The wound contacting element and wound covering element may be optionally combined into a single element.


The wound covering element and vacuum connection tube may optionally be combined into a single element.


The wound contacting element, wound covering element and vacuum connection tube may be optionally combined into a single element.


The vacuum source may be any available and may be optionally mechanically powered by, for example, a compressed spring and comprise a syringe as the vacuum generating means as is known in the prior art; or electrically powered, for example a vacuum pump. Preferably, the vacuum source may be capable of generating vacuums in the range of −10 mmHg to −250 mmHg relative to atmospheric pressure. More preferably, the vacuum source is a vacuum pump capable of generating vacuums in the range of −10 mmHg to −250 mmHg relative to atmospheric pressure. The pump may generate a vacuum by any convenient means; diaphragm pumps, peristaltic pumps, Venturi-effect pumps and other displacement pumps may be suitable for this purpose.


The vacuum source may preferably be below 500 g in weight, more preferably below 100 g in weight and even more preferably below 50 g in weight.


In cases where the vacuum source is electrically powered, the power source may be mains supplied, a battery supply or a locally generated supply such as a clockwork generator, a solar cell, a thermo cell or a kinetic autorelay type of power source. Preferably the power source may be a battery.


In cases where the power source is a battery, the battery may be disposable or rechargeable. When the battery is rechargeable, recharging may be achieved via a charging station for the vacuum housing or for the battery itself. Battery life may be preferably longer than 12 hours, more preferably longer than 24 hours and even more preferably longer than 72 hours. The battery may preferably be below 100 g in weight, more preferably below 50 g in weight.


The power and vacuum sources may be housed separately or together. Preferably they are housed together. When housed, the combined weight of the power and vacuum source and housing may be preferably less than 1 kg, more preferably less than 500 g, more preferably still less than 200 g. The housing may be of any geometry but is preferably adapted so as to be convenient for the patient and/or carer to handle and carry. It may also preferably be of dimensions below 15×15×6 cm.


The apparatus of the first aspect of the present invention may be applied to wounds for their management. The general principle of the apparatus is the application of the wound contacting element to the wound, covering the wound contacting element with the wound covering element and coupling the wound contacting element to a vacuum source via a vacuum connection tube. As mentioned above, two or more of these elements may be provided as a single entity. Preferably for largely two-dimensional wounds, the wound contacting element and the wound covering element may be a single entity. This combined entity may contain the pressure-sensitive valve in its top surface and may be attached to the perimeter of the wound by appropriate means. Attachment of the dressing to a patient may be achieved by the application of negative pressure alone, in the absence of a bonding means or may be achieved via a bonding means. Attachment may preferably be achieved by a bonding means, for example a pressure sensitive adhesive applied to the skin contacting surface of the wound covering element. When the bonding means is a pressure sensitive adhesive, it may preferably be a poly(acrylate)- or silicone-based formulation.


According to a second aspect of the present invention there is provided apparatus for the application of topical negative pressure therapy to a wound site, the apparatus comprising: a wound covering element that provides a substantially airtight seal over the wound; a vacuum connection tube connecting the wound covering element to a vacuum source; a vacuum source connected to a distal end of the vacuum connection tube; the wound covering element having valve means associated therewith which permits only fluid flow out of a wound cavity defined by the wound covering element and the wound.


When the wound contacting element and the wound covering element are in place, the vacuum source is activated and the vacuum connection tube, preferably attached to the vacuum source, may be connected to the wound covering element via an aperture or valve in the wound covering element. At any point during the application of negative pressure therapy, the coupling of vacuum connection tube to the wound covering element can be reversibly broken and re-established at the convenience of the patient or carer.


In an embodiment of the apparatus according to either the first or second aspects of the present invention the dressing wound covering element may comprise a one-way valve as mentioned above, the valve essentially being able to allow fluid in the form of air to be withdrawn from the wound cavity defined by the wound covering element via the vacuum connection tube. As mentioned above the vacuum connection tube may preferably be repeatably connectable and disconnectable to the dressing/wound covering element without damage thereto such that the vacuum source may be removed by the patient and the dressing left in place but sealed against the ingress of bacteria and potential infection, for example, by the presence of the one-way valve in the wound covering element. The one-way valve means may be a simple plastics material self-sealing valve as are available commercially for many diverse applications outside of the field of TNP therapy such as those sold under the trade mark “miniValve” by Mini Valve International, for example.


Desirably the vacuum connection tube may be attached to the dressing/wound covering element by non-adhesive means so as to facilitate repeated connection/disconnection thereof without damaging the wound covering element film material. In this regard the vacuum connection tube may be connected by “sucker” means at the dressing end of the vacuum connection tube, the sucker means being, for example, in the form of a cup-shaped, domed or bell-shaped conformable plastics material member which is in fluid communication with the vacuum connection tube and which member which may be placed over the valve means in the wound covering element and seal with surrounding wound covering element material, the sucker means being held in place on the dressing/wound covering element by the vacuum generated by the vacuum source itself. Disconnection of the vacuum connection tube may then be effected merely by turning off the power source to the vacuum source or by breaking the seal of the sucker by lifting its edge (NB the sucker can easily be removed by this intentional manipulation but cannot easily be accidentally dislodged by vertical extensive force e.g. pulling on the vacuum connection tube).


When the wound contacting element becomes saturated with wound exudate, the vacuum connection tube can be disconnected and the wound contacting element and wound covering element (or a physical combination of the two) can be exchanged for a new set.


Wounds suitable for management by the apparatus that is the subject of this invention include injuries to soft and hard tissue, including the skin, muscle, cartilage, tendons, bone and internal organs.


In the second aspect of the invention a wound contacting element of highly absorbent material may not be present and wound exudate may be aspirated from the wound cavity to a remote waste receptacle by the vacuum source.





BRIEF DESCRIPTION OF THE DRAWINGS

In order that the present invention may be more fully understood examples will now be described by way of illustration only with reference to the accompanying drawings, of which:



FIG. 1 shows a schematic cross section of an embodiment of apparatus according to the present invention and a wound being treated by TNP therapy;



FIGS. 2A to 2C which show the arrangement of FIG. 1 simplified and the progression of saturation of a wound contacting element; and



FIG. 3 illustrates a liquid contact triggered valve.





DETAILED DESCRIPTION OF SOME EXEMPLIFYING EMBODIMENTS

Referring now to the drawings and where the same features are denoted by common reference numerals.



FIG. 1 shows a schematic cross section through a wound 10 having an embodiment of apparatus 12 according to the present invention applied to it for the purpose of TNP therapy of the wound. The wound 10 has a wound contacting element 14 placed in the cavity defined by the wound, the wound contacting element being roughly level with surrounding sound skin 16. A wound covering element 18 is applied over the wound to contact and seal with the surrounding sound skin by means of a layer of pressure sensitive adhesive (not shown) coated onto the skin contacting surface of the wound covering element material. The wound covering element 18 has an aperture 20 in the area above a part of the wound and the wound contacting element 14. A one-way valve 22 is positioned in the aperture 20 to permit fluid in the form of air to be extracted from the wound cavity 24 defined by the wound covering element 18 and the wound 10 itself. A vacuum source 26 in the form, in this example, of a battery powered vacuum pump is connected to the wound cavity by a vacuum connection tube 28 and a cup-shaped connection member 30 having an aperture 32 therein to accept the end of the vacuum connection tube 28. The cup-shaped member 30 has a flange portion 34 which seats onto the upper surface 36 of the wound covering element 18 material and seals therewith. The valve 22 has an orifice 40 which is normally closed due to the resilience of the material from which it is moulded, for example, silicone plastics based material. The orifice 40 is in the form of a slit normally closed by two lips 42, 44 (the shape of the valve orifice may be likened to a flat bladed screwdriver and the valve orifice 40 in FIG. 1 runs normal to the plane of the page). The valve 22 is initially held in and sealed to the wound covering element material 18 by a flange portion 46 bearing against the underside of the wound covering element 18 material and a circular shoulder 48 and recess 50 which is held in the aperture 20. To evacuate the wound cavity 24, the vacuum pump 26 is started and the cup-shaped member 30 placed on the wound covering element material above the valve 22 and the reduction in pressure within the wound cavity 24 causes the cup-shaped member 30 to be sealed securely to the dressing by the excess pressure of the surrounding ambient air. As the vacuum in the wound cavity develops, the wound covering element 18 is pushed down against the wound contacting element 14 by ambient air pressure and the wound contacting element 14 compressed against the wound surface to apply TNP therapy thereto.


Whilst it is perfectly feasible for the lower surface of the flange portion 34 of the cup-shaped member 30 to be adhesively coated and to be so retained on the wound covering element material, in this example retention of the vacuum connection tube 28 to the wound dressing is solely by ambient air pressure as described above. In case the patient wishes to detach the vacuum pump 26 and leave it behind this may simply be achieved by turning off the pump 26 and allowing the vacuum to degrade and removing the cup-shaped connection member 30. In this case the valve 22 is self-sealing prevents access of bacteria and the like to the wound cavity 24.


The valve 22 exemplified above is a miniValve (trade mark) supplied by Mini Valve International. However, this valve is merely exemplary and many other types of suitable valves are available commercially.


For example International Patent Application No PCT/EP2008/063046 discloses a composition which coalesces on hydration and which can be used to provide a valve which closes upon contact with liquid. The application is included fully herein by way of reference but briefly discloses a suitable composition that enables a new physical transformation. The physical transformation in question involves the conversion of a first stable physical geometry into a second stable physical geometry upon hydration, wherein hydration enables the self-coalescence (fusion) of spatially separated elements or surfaces of the first stable physical geometry.


Each geometry is physically stable. Thus, immersion of the first stable physical geometry in excess solution results in conversion to the second stable physical geometry without significant loss of the material mass by dissolution. That is, the second stable geometry is insoluble, or has only very limited solubility, in the excess solution. The second stable physical geometry is, at least substantially, self supporting such that it is able to retain its shape when is excess solution, or when removed therefrom. In typical preferred forms in the second stable physical geometry the material of the invention is a gel or gel like material.


A feature of the composition is the physical homogeneity of the object in both the first and second physical geometries.


The novel transformation is enabled by construction of the object, at least in part, from materials that can exist in physically stable forms in the dry state and the hydrated state. Furthermore, the hydrated state of the material must be sufficiently self-cohesive, even when immersed in excess solvent, to enable fusion to occur. This, we believe, is a property unique to a limited range of states of matter, some of which we prepare to exemplify this invention.


In broad terms the composition of matter when formed into an object of suitable geometry, can self-coalesce upon hydration in a suitable solvent.


According to a first aspect of the composition there is provided a high molecular mass cationic polymer material having a first state which includes at least two separate but adjacent surfaces and a second state in which the polymer consists of a homogeneous body, wherein the material transitions from the first state to the second state upon hydration.


Thus, on hydration the material expands and the surfaces merge or coalesce to result in a body of self supporting material, typically a gel or gel-like material, which has uniform properties in any dimension. Surfaces and other boundaries within the body of material are absent. Furthermore the body of material is insoluble, or at least of limited solubility in the hydrating solvent and is able to retain its physical geometry under leading (for example gravity).


The term ‘suitable geometry’ is taken to describe an arrangement where separate (for example spatially separate, but not necessarily physically separate) elements or surfaces of the object are sufficiently proximate to enable coalescence upon hydration-induced expansion.


The term ‘suitable solvent’ is taken to describe a fluid (liquid or gas) that can be absorbed be the object, causing expansion and a change in the physical properties of the object (e.g. surface energy). The suitable solvent is typically and preferably an aqueous medium.


The term ‘self-coalesce’ is taken to describe the transformation of two or more spatially separated physically homogeneous elements into a single physically homogeneous element or of fusion of previously spatially separated surfaces of the same element.


Suitable compositions of matter from which objects can be formed are those comprised, entirely or in part, of high average molecular weight cationic polymers including zwitterionic (carrying both anionic and cationic charge) polymers with a cationic charge bias. The cationic polymer may be, or may be a derivative of, a synthetic or a naturally occurring polymer. Preferably, the cationic polymer is one carrying amine functionality. More preferably, the cationic polymer is a polysaccharide. More preferably still, the cationic polymer is chitosan or a derivative of chitosan. The chitosan may be derived from any source, marine or fungal, and is preferably of a weight average molecular weight (Mw) exceeding 10 kDa (kilodaltons), more preferably exceeding 100 kDa and most preferably exceeding 200 kDa.


Where the polymer is a derivative of chitosan, it is preferably a carboxylated derivative. More preferably, it is a carboxyalkyl derivative of chitosan. More preferably still, it is a carboxymethyl derivative of chitosan. The carboxymethyl derivative of chitosan is preferably of a weight average molecular weight exceeding 50 kDa, more preferably exceeding 100 kDa, especially exceeding 500 kDa, more especially exceeding 600 kDa and especially 700 kDa or more.


Carboxymethylation is preferably achieved using known reagents: a base and chloroacetic acid or preferably a neutral salt of chloroacetic acid such as sodium chloroacetate. Preferably, the reaction is carried out in a single step: chitosan fibres or (less preferably) particles being immersed in a solution of reagents or vice versa. Suitable reaction solvents include mixtures of an alcohol with water. The alcohol may be any known but is preferably a non-solvent for chitosan and carboxymethylchitosan, for example isopropanol. The base may be any known but is preferably a water-soluble inorganic base such as sodium hydroxide or potassium hydroxide, preferably sodium hydroxide.


According to a second aspect of the composition there is provided a method of preparing high molecular mass carboxymethylchitosan comprising the steps:

    • a. mixing chitosan with a solution of a base and chloroacetic acid, or a neutral salt thereof, dissolved in a reaction solvent comprising a mixture of an alcohol and water;
    • b. allowing the reaction to proceed at ambient temperature for at least 8 hours whilst ensuring adequate exposure of the chitosan to the reaction solvent;
    • c. when the reaction is complete, washing the reaction product in excess alcohol-containing solvent;


wherein the volume (in millilitres) of the reaction solvent is at least 20-times the mass (in grams) of chitosan.


A high molecular mass carboxymethyl chitosan preferably comprises a carboxymethyl chitosan having a mass of at least 500 kDa, more especially at least 600 kDa and especially 700 kDa or more.


In one preferred embodiment the volume of reaction solvent (in millilitres) exceeds the mass of chitosan (in grams) by more than 20 but less than 70-times, more preferably by more than 30-times but less than 40-times.


In another preferred embodiment the mass of sodium chloroacetate exceeds the mass of chitosan by not more than 2-times, more preferably by not more that 1.2-times.


In a preferred embodiment, the alcohol of the reaction solvent is isopropanol.


In further preferred embodiments the reaction is carried out at ambient temperature for a period of at least 8 hours, more preferably for at least 15 hours and even more preferably for at least 18 hours.


In a particularly preferred embodiment, the alcohol of the reaction solvent is isopropanol, the mass of sodium chloroacetate is not more than twice (more especially not more than 1.2 times) the mass of the chitosan and the reaction is allowed to proceed for at least 8 hours.


When the chitosan is provided for reaction in powder or fibre form, this material should be adequately exposed to the turbid reaction solvent throughout the duration of the reaction. This process can be facilitated by any means known to the artisan but can be simply achieved by rolling the reaction vessel, for example.


When the reaction is complete, reaction by-products detrimental to the stability of the product, such as sodium chloride or sodium hydroxyacetate, should be removed to the maximum extent feasible. To achieve this, the reaction product is washed, preferably in one or more steps, in excess solvent comprised of at least 60 parts alcohol (such as ethanol) and 40 parts water (60:40).


More than one washing step is preferred and, when this is the case, the first wash step has preferably a higher water content than subsequent steps, with water content decreasing in every wash step. For example, a suitable two-step wash procedure involves a first wash in excess solvent comprised of at least 60 parts ethanol and 40 parts water (60:40) and a second wash in excess solvent comprised of at least 90 parts ethanol and 10 parts water (90:10).


Thus in a preferred embodiment the reaction product is washed in a plurality of washing stages, each employing an excess of a solvent comprising alcohol and water, wherein in each succeeding stage the solvent consists of a higher proportion of alcohol. Preferably the alcohol is ethanol


It is essential that wash solvents always includes some water to avoid excessive dehydration of the product, which can result in brittleness.


The composition of the wash solvent may include any suitable alcohols such as ethanol, isopropanol or methanol. Ethanol is preferred.


The product resulting from washing and solvent removal can be sterilised by methods typical for the sterilisation of medical devices, for example gamma-irradiation, electron-beam irradiation or ethylene oxide treatment.


Prior to radiation-based sterilisation, the washed reaction product should be adequately solvent-free. This can be achieved by any drying process known to the skilled artisan. A preferred drying process is conducted at temperatures not exceeding 40° C., more preferably not exceeding 30° C. Preferably, solvent removal is achieved by placing the material under a sub-atmospheric pressure. The pressure is preferably less than 500 mbar, more preferably less than 1000 mbar. The duration of the drying process, when achieved by vacuum drying, preferably exceeds 8 hours, more preferably exceeding 12 hours.


The weight average molecular weight of the material following washing and radiation sterilisation is preferably greater than 120 kDa, more preferably greater than 130 kDa and after washing and ethylene oxide sterilisation is preferably greater than 400 kDa, more preferably greater than 500 kDa. It is important that these molecular weights are obtained to avoid mechanical integrity problems in the final product and dissolution problems when exposed to fluid.


Additives and co-components can be added at any stage of the above process, prior to terminal sterilisation. These agents may be any suitable for a topical or internal medical application, such as analgesics, anaesthetics, antimicrobial agents, anti-cancer agents, nicotine or nicotine substitutes or other synthetic or naturally-derived pharmaceuticals including peptides, proteins such as growth factors or retardants, enzymes (e.g. those facilitating tissue debridement), DNA or RNA fragments.


When the additive is an antimicrobial agent, it may be for example: silver or silver compounds, iodine or iodine compounds, quaternary amine-based antimicrobials such as polyhexamethylenebiguanide or chlorhexidene, antibiotics such as gentamycin, vancomycin or a peptide-based agent.


When silver is introduced into the formulation, and the formulation is carboxymethylchitosan-based, addition is preferably achieved by immersion in a solvent mixture of a similar composition as that applied during the carboxymethylation process.


In a third aspect, the composition can be used to provide a method of fusing two or more solid surfaces, wherein the surfaces are initially separate (in particular, spatially separated) but adjacent surfaces of one or more object(s) comprising a self-coalescing material as herein described, notably the high molecular mass polymer material of the first aspect of the invention. The method comprises the step of immersing said surfaces in an aqueous medium and thus hydrating and expanding the self-coalescing material. In one embodiment, the surfaces are initially spatially separated surfaces of the same object. Alternatively, the surfaces are initially spatially separated surfaces of different objects. These alternatives are not mutually exclusive. The surfaces may be the surfaces of fibres, for example in a woven or, more especially, a non-woven fibrous material. In such materials, the surfaces may have portions which are spaced apart and portions which, while being separate, are in contact.


Objects fabricated from the compositions defined above, and suitable for the method, need to be suitably designed to enable coalescence upon hydration. For example, an isolated linear object would not have the opportunity to self-coalesce upon hydration. In contrast, a pair of isolated but adjacent linear objects would have the opportunity to swell and coalesce upon hydration. In this context, ‘adjacent’ means located within about 10 mm of one another. Thus, suitable objects can be defined as containing, at least in part, spatially separated elements or surfaces located within about 10 mm of one another. Preferably, the spatially separated elements or surfaces are located within 5 mm of one another. More preferably, the spatially separated elements or surfaces are located within 1 mm of one another. In some cases, for example fibre based materials, at least parts of adjacent surfaces may be in contact.


Preferred physical formats that meet the above description are fibre-based materials such as woven and non-woven materials. Other suitable formats include knits, open-celled foams and laminates including corrugated materials. More complex arrangements can be fabricated by methods known to one skilled in the art, such as lithography, micromachining and electrospinning. The composition and its uses is not restricted to formats of high open area but includes solid monoliths. Fibre based materials are preferred and fibre-based non-woven materials are particularly preferred.


The composition in use is not restricted to objects consisting exclusively of self-coalescent material, but includes composites, for example composites of common medical device formats and self-coalescent material and surface-coatings, for example implantable metal- or biomaterial based devices including soft-tissue substitutes and joint implants. Composites suitable for topical and internal wound management include those combining polyurethane based materials, such as foams, slabs and films with self-coalescent materials, for example in powdered or, more especially, fibrous form.


When devices comprised, at least in part, of the compositions are immersed in a fluid, they absorb fluid, become swollen and self-coalesce across contact points. Use is not restricted to specific compositions or specific fluids, but in preferred forms and for preferred end-sues, the fluid is most preferably water based. For example, in the case of carboxymethylchitosan-based materials, the fluid is preferably water based. Examples of water based fluids include water or a solution of water, such as saline or a biologically-derived fluid such as whole blood, blood plasma, serum, saliva, wound exudate or bone marrow aspirate.


The novel material properties of the described self-coalescing materials can be exploited in a range of applications, for example in irreversible fluid valving systems and moulding materials.


EXAMPLES
Example 1

Generation of Self-Coalescing Carboxymethylchitosan Fibres


A) Synthesis


Immediately prior to reaction, sodium chloroacetate (1.75 g) was dissolved in 4% aqueous sodium hydroxide solution (7 ml). This solution was added to isopropanol (45 ml) and shaken vigorously, resulting in a turbid suspension. This mixture was added to a vessel containing chitosan fibres (1.50 g), the container sealed and rolled at approximately 60 rpm for 18 hours.


B) Washing Steps


B1) After step A, the fibres were removed from the now clear reaction solvent and transferred to a vessel containing 99:1 ethanol:water (200 ml). The material was disturbed every 15 minutes for 1 hour, after which time the material was removed and physically dried by the application of hand pressure between several layers of absorbent material. Following gross drying, the material was vacuum dried at ambient temperature overnight.


B2) After step A, the fibres were removed from the now clear reaction solvent and transferred to a vessel containing 60:40 ethanol:water (200 ml). The material was disturbed every 15 minutes for 1 hour, after which time the material was removed and transferred to a second vessel containing 90:10 ethanol:water (200 ml). The material was disturbed every 15 minutes for 1 hour, after which time the material was removed and physically dried by the application of hand pressure between several layers of absorbent material. Following gross drying, the material was vacuum dried at ambient temperature overnight.


Example 2

Generation of Self-Coalescing Carboxymethylchitosan Fibres (Scale-Up)


Immediately prior to reaction, sodium chloroacetate (96.8 g) was dissolved in 4% aqueous sodium hydroxide solution (387 ml). This solution was added to isopropanol (2490 ml) and shaken vigorously, resulting in a turbid suspension. This mixture was added to a vessel containing chitosan fibres (83.0 g), the container sealed and rolled at approximately 60 rpm for 18 hours. After this time, the fibres were removed from the now clear reaction solvent and transferred to a vessel containing 99:1 ethanol:water (2000 ml). The material was disturbed every 15 minutes for 1 hour, after which time the material was removed and physically dried by the application of hand pressure between several layers of absorbent material. Following gross drying, the material was vacuum dried at ambient temperature overnight.


Example 3

Radiation Sterilisation of Self-Coalescing Carboxymethylchitosan Fibres


The material resulting from Example 1, step B2 was packaged in gas-permeable sterilisation pouches and sterilised by gamma irradiation at 30-40 kGy. The molecular weight of the material pre- and post-sterilisation was determined by gel permeation chromatography. The molecular weight prior to sterilisation was approximately Mw 700 kDa; the molecular weight post-sterilisation was approximately Mw 140 kDa. The molecular weight change in the material, although substantial, was such that the physical properties of the material were not significantly altered by sterilisation.


Example 4

Ethylene Oxide Sterilisation of Self-Coalescing Carboxymethylchitosan Fibres


The material resulting from Example 1, step B2 was packaged in gas-permeable sterilisation pouches and sterilised by ethylene oxide treatment. The molecular weight of the material pre- and post-sterilisation was determined by gel permeation chromatography. The molecular weight prior to sterilisation was approximately Mw 700 kDa; the molecular weight post-sterilisation was approximately Mw 575 kDa. The molecular weight change in the material was such that the physical properties of the material were not significantly altered by sterilisation.


Example 5

Water Absorbency of Self-Coalescing Carboxymethylchitosan Fibres


The material resulting from Example 3 (100 mg) was immersed in water (4 ml) for 1 minute and withdrawn. Excess liquid was allowed to drain and then the hydrated transparent mass was weighed. The material was calculated to absorb approximately 25-times its own mass in water without significant dissolution.


Example 6

Serum Absorbency of Self-Coalescing Carboxymethylchitosan Fibres


The material resulting from Example 3 (100 mg) was immersed in serum (4 ml) for 1 minute and withdrawn. Excess liquid was allowed to drain and then the hydrated transparent mass was weighed. The material was calculated to absorb approximately 13-times its own mass in serum without significant dissolution.


Example 7

Self-Coalescence of Carboxymethylchitosan Fibres in Water


The material resulting from Example 3 (100 mg) was immersed in water (4 ml) for 1 minute and withdrawn. Excess liquid was allowed to drain and then the hydrated transparent mass was allowed to stand for 4 hours. After this time, the individual fibres of the material had self-coalesced and the material was then effectively a homogeneous, elastic hydrogel, able to stably retain its physical geometry under loading (FIG. 2).


Example 8

Self-Coalescence of Carboxymethylchitosan Fibres in Serum


The material resulting from Example 3 (100 mg) was immersed in serum (4 ml) for 1 minute and withdrawn. Excess liquid was allowed to drain and then the hydrated transparent mass was allowed to stand for 4 hours. After this time, the individual fibres of the material have self-coalesced and the material as effectively a homogeneous, elastic hydrogel, able to stably retain its physical geometry under loading.



FIGS. 2A to 2C show stages in the absorption of wound exudate into the wound contacting element 14. The basic arrangement may be the same as that of FIG. 1, however, the drawings of FIG. 2 have been simplified. FIG. 2A shows a clean dressing newly installed in the wound 10 and without any exudate being taken up; FIG. 2B shows the wound contacting element 14 partially full of exudate; and, FIG. 2C shows the wound contacting element 14 saturated with wound exudate. However, the nature of the wound contacting element material 14 is such that no liquid is aspirated by the vacuum connection tube 28 out of the wound cavity 24 or indeed out of the wound contacting element 14 itself.



FIG. 3 shows paradigms of the conversion of a first stable physical geometry into a second stable physical geometry upon hydration, wherein hydration enables the self-coalescence (fusion) of spatially separated elements of the first stable physical geometry. In case A, the self-coalescence comprises the fusion of spatially separated surfaces of a single element; in case B the surfaces are adjacent surfaces of two separate elements.


The Examples described below are based on the use of the apparatus arrangement shown in FIG. 1 and/or FIG. 2 and/or FIG. 3.


Example 1

Application of apparatus of FIG. 1 to ex vivo cavity wound. A 5 cm diameter, 5 cm depth cavity wound was cut by scalpel into a porcine leg joint. The musculature in the area of the wound cavity was injected with saline to ensure that the tissue was adequately hydrated for the duration of the experiment. The wound cavity was packed with two wound contacting elements of non-woven balls of carboxymethylchitosan fibre and the wound cavity and filling was covered over with an adhesive silicone gel sheet CicaCare (trade mark) made by Smith & Nephew Medical Ltd with a central 5 mm diameter aperture 20. A luer loc fitting attached to a coiled vacuum hose was inserted through the aperture and connected to a battery-powered vacuum source Pac-Vac (trade mark) made by Virtual Industries Inc. Immediate contraction of the wound margin was observed and the non-woven balls were compressed down to be flush with the surface of the skin. The system was left in place for 8 hours undisturbed, after which time no fluid had exited the cavity packing but had collected within it.


Example 2

Assembly of apparatus based on FIG. 1 having a wound covering element 14 of Allevyn Adhesive (trade mark) made by Smith & Nephew Medical Ltd. A 3 mm diameter aperture in the top film of Allevyn Adhesive was created using a biopsy punch. Over this aperture was bonded a silicone elastomer dome miniValve (trade mark) made by Mini Valve International B. V., part number DO 072.004. A miniature vacuum source made by Virtual Industries Inc., PAC-VAC V3200 (trade mark) was coupled by vacuum tubing 28 to a hand-made silicone rubber cup 30.


Example 3

Usage of apparatus based on Allevyn Adhesive as in Example 2. A 5 cm diameter, 5 cm depth cavity wound was cut by scalpel into a porcine leg joint. The musculature in the area of the wound cavity was injected with saline to ensure that the tissue was adequately hydrated for the duration of the experiment. The wound cavity was packed with wound contacting element 14 comprising two non-woven balls of carboxymethylchitosan fibre and the wound cavity 24 and filling was covered over with the modified Allevyn Adhesive dressing described in Example 2. The vacuum source, as described in Example 2, was turned on and the vacuum tubing cup placed over the dome valve positioned centrally on the Allevyn Adhesive. Immediate contraction of the Allevyn Adhesive dressing and the wound margin was observed and the non-woven balls were compressed down to be flush with the surface of the skin. The system was left in place for 8 hours undisturbed, after which time no fluid had exited the cavity packing but had collected within it.


Example 4

Usage of apparatus based on Allevyn Adhesive as described in Example 2. A 5 cm diameter, 5 mm depth shallow wound was cut by scalpel into a porcine leg joint. The musculature in the area of the wound was injected with saline to ensure that the tissue was adequately hydrated for the duration of the experiment. The wound was covered with a non-woven sheet of carboxymethylchitosan as the wound contacting element 14 and the wound and non-woven sheet was covered over with the modified Allevyn Adhesive dressing described in Example 2 as the wound covering element 18. The vacuum source, as described in Example 2, was turned on and the vacuum tubing cup placed over the dome valve positioned centrally on the Allevyn Adhesive. Immediate contraction of the Allevyn Adhesive dressing was observed. The system was left in place for 8 hours undisturbed, after which time no fluid had exited the wound dressing but had collected within it.


Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.


Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.


Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.

Claims
  • 1. An apparatus for the application of topical negative pressure therapy to a wound, the apparatus comprising: a wound covering element configured to be positioned over a wound; anda self-coalescing liquid blocking material configured to be positioned in a flow-path between the wound and a vacuum source.
  • 2. The apparatus of claim 1, wherein the wound covering element comprises an aperture.
  • 3. The apparatus of claim 2, further comprising a vacuum connection conduit configured to be connected to the wound covering element.
  • 4. The apparatus of claim 1, wherein the liquid blocking material comprises a valve that closes upon contact with wound exudate and blocks all liquid transport beyond itself away from the wound site, the valve being open prior to contact with wound exudate.
  • 5. The apparatus of claim 1, wherein the wound covering element additionally comprises an adhesive configured for adhering to a portion of skin surrounding the wound.
  • 6. The apparatus of claim 1, wherein the liquid blocking material comprises self-coalescing fibers.
  • 7. The apparatus of claim 2, wherein the liquid blocking material is configured to be positioned at the aperture.
  • 8. The apparatus of claim 1, wherein the wound covering element is substantially impermeable to the flow of liquid, but is substantially permeable to the transmission of water vapor.
  • 9. The apparatus of claim 1, wherein the wound covering element is a transparent polyurethane.
  • 10. The apparatus of claim 1, wherein the wound covering element comprises an absorbent foam.
  • 11. The apparatus of claim 1, wherein the vacuum source is electrically powered.
  • 12. The apparatus of claim 1, wherein the wound covering element and the self-coalescing liquid blocking material are combined into a single element.
  • 13. A method for the application of topical negative pressure therapy to a wound, the method comprising: applying a wound covering element over a wound; anddelivering negative pressure to the wound from a source of negative pressure;wherein a self-coalescing liquid blocking material is positioned in a flow-path between the wound and the source of negative pressure.
  • 14. The method of claim 13, wherein the wound covering element comprises an aperture.
  • 15. The method of claim 14, wherein negative pressure is delivered through the aperture.
  • 16. The method of claim 15, wherein negative pressure is delivered through a vacuum connection conduit connected to the wound covering element.
  • 17. The method of claim 13, wherein the source of negative pressure is electrically powered.
  • 18. The method of claim 13, wherein the liquid blocking material comprises self-coalescing fibers.
Priority Claims (1)
Number Date Country Kind
0722820 Nov 2007 GB national
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/973,111, filed May 7, 2018, which is a divisional application of U.S. application Ser. No. 14/254,807, filed Apr. 16, 2014, which is a continuation application of U.S. application Ser. No. 12/744,055, filed May 20, 2010, which is a U.S. National Phase of the PCT International Application No. PCT/GB2008/051088 filed on Nov. 20, 2008, designating the United States and published on May 28, 2009 as WO 2009/066104, which claims priority to Great Britain Patent Application No. 0722820.8, filed Nov. 21, 2007. The disclosure of these prior applications is incorporated by reference in their entirety and should be considered a part of this specification.

US Referenced Citations (736)
Number Name Date Kind
695270 Beringer Mar 1902 A
1480562 Hugo et al. Jan 1924 A
2280915 Johnson Apr 1942 A
2367690 Purdy Jan 1945 A
2568933 Robbins Sep 1951 A
2632443 Lesher Mar 1953 A
2682873 Idnis et al. Jul 1954 A
2910763 Lauterbach Nov 1959 A
3115138 McElvenny et al. Dec 1963 A
3367332 Groves Feb 1968 A
3486504 Austin, Jr. et al. Dec 1969 A
3572340 Lloyd et al. Mar 1971 A
3610238 Rich, Jr. Oct 1971 A
3874387 Barbieri Apr 1975 A
3972328 Chen Aug 1976 A
3993080 Loseff Nov 1976 A
4029598 Neisius et al. Jun 1977 A
RE29319 Nordby et al. Jul 1977 E
4102342 Akiyama et al. Jul 1978 A
4112947 Nehring Sep 1978 A
4136696 Nehring Jan 1979 A
4184510 Murry et al. Jan 1980 A
4217894 Franetzki Aug 1980 A
4219019 Coates Aug 1980 A
4224945 Cohen Sep 1980 A
4250882 Adair Feb 1981 A
4316466 Babb Feb 1982 A
4382441 Svedman May 1983 A
4465485 Kashmer et al. Aug 1984 A
4468227 Jensen Aug 1984 A
4525166 Leclerc Jun 1985 A
4534356 Papadakis Aug 1985 A
4551141 McNeil Nov 1985 A
4573965 Russo Mar 1986 A
4608041 Nielsen Aug 1986 A
4655754 Richmond et al. Apr 1987 A
4655766 Theeuwes et al. Apr 1987 A
4681562 Beck et al. Jul 1987 A
4710165 McNeil et al. Dec 1987 A
4728499 Fehder Mar 1988 A
4778446 Jensen Oct 1988 A
4778456 Lokken Oct 1988 A
4792328 Beck et al. Dec 1988 A
4795435 Steer Jan 1989 A
4813942 Alvarez Mar 1989 A
4820284 Hauri Apr 1989 A
4826494 Richmond et al. May 1989 A
4828546 McNeil et al. May 1989 A
4921488 Maitz et al. May 1990 A
4936834 Beck et al. Jun 1990 A
4950483 Ksander et al. Aug 1990 A
4969880 Zamierowski Nov 1990 A
4972829 Knerr Nov 1990 A
4979944 Luzsicza Dec 1990 A
4994022 Steffler et al. Feb 1991 A
5010115 Grisoni Apr 1991 A
5055198 Shettigar Oct 1991 A
5056510 Gilman Oct 1991 A
5060642 Gilman Oct 1991 A
5073172 Fell Dec 1991 A
5080493 McKown et al. Jan 1992 A
5100396 Zamierowski Mar 1992 A
5134994 Say Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5152757 Eriksson Oct 1992 A
5167613 Karami et al. Dec 1992 A
5176663 Svedman et al. Jan 1993 A
5181905 Flam Jan 1993 A
5215519 Shettigar Jun 1993 A
5234419 Bryant et al. Aug 1993 A
5238732 Krishnan Aug 1993 A
5249709 Duckworth et al. Oct 1993 A
5261893 Zamierowski Nov 1993 A
5266326 Barry et al. Nov 1993 A
5266928 Johnson Nov 1993 A
5279608 Cherif Cheikh Jan 1994 A
5328614 Matsumura Jul 1994 A
5333760 Simmen Aug 1994 A
5358494 Svedman Oct 1994 A
5380280 Peterson Jan 1995 A
5437651 Todd et al. Aug 1995 A
5445604 Lang Aug 1995 A
5456745 Roreger et al. Oct 1995 A
5489280 Russell Feb 1996 A
5498338 Kruger et al. Mar 1996 A
5527293 Zamierowski Jun 1996 A
5536233 Khouri Jul 1996 A
5549584 Gross Aug 1996 A
5562107 Lavender et al. Oct 1996 A
5582596 Fukunaga et al. Dec 1996 A
5583114 Barrows et al. Dec 1996 A
5609271 Keller et al. Mar 1997 A
5612050 Rowe et al. Mar 1997 A
5624423 Anjur et al. Apr 1997 A
5632731 Patel May 1997 A
5636643 Argenta et al. Jun 1997 A
5643189 Masini Jul 1997 A
5645081 Argenta et al. Jul 1997 A
5660823 Chakrabarti et al. Aug 1997 A
5662583 Khouri Sep 1997 A
5676634 Khouri Oct 1997 A
5678564 Lawrence Oct 1997 A
5695445 Khouri Dec 1997 A
5700477 Rosenthal Dec 1997 A
5701917 Khouri Dec 1997 A
5707499 Joshi et al. Jan 1998 A
5717030 Dunn et al. Feb 1998 A
5733337 Carr, Jr. et al. Mar 1998 A
5747064 Burnett et al. May 1998 A
5759570 Arnold Jun 1998 A
5776098 Silver et al. Jul 1998 A
5776193 Kwan et al. Jul 1998 A
5785688 Joshi et al. Jul 1998 A
5817145 Augustine et al. Oct 1998 A
5830496 Freeman Nov 1998 A
5833646 Masini Nov 1998 A
5834007 Kubota Nov 1998 A
5843011 Lucas Dec 1998 A
5852126 Barnard et al. Dec 1998 A
5868933 Patrick et al. Feb 1999 A
5874500 Rhee et al. Feb 1999 A
5876611 Shettigar Mar 1999 A
5928265 Fleischmann Jul 1999 A
5945115 Dunn et al. Aug 1999 A
5962010 Greff et al. Oct 1999 A
5964723 Augustine Oct 1999 A
5998472 Berger et al. Dec 1999 A
6010527 Augustine et al. Jan 2000 A
6013097 Augustine et al. Jan 2000 A
6071267 Zamierowski Jun 2000 A
6093160 Augustine et al. Jul 2000 A
6103951 Freeman Aug 2000 A
6110197 Augustine et al. Aug 2000 A
6117111 Fleischmann Sep 2000 A
6135116 Vogel et al. Oct 2000 A
D434150 Tumey et al. Nov 2000 S
6142982 Hunt Nov 2000 A
6143352 Clark et al. Nov 2000 A
6165201 Sawhney et al. Dec 2000 A
6168788 Wortham Jan 2001 B1
6168800 Dobos et al. Jan 2001 B1
6176307 Danos et al. Jan 2001 B1
6214332 Askill et al. Apr 2001 B1
6225523 Masini May 2001 B1
6248084 Augustine et al. Jun 2001 B1
6252129 Coffee Jun 2001 B1
6254567 Treu et al. Jul 2001 B1
6255552 Cummings et al. Jul 2001 B1
6257847 Silver et al. Jul 2001 B1
6261283 Morgan et al. Jul 2001 B1
6267740 Augustine et al. Jul 2001 B1
6287521 Quay et al. Sep 2001 B1
6291050 Cree et al. Sep 2001 B1
6293917 Augustine et al. Sep 2001 B1
6345623 Heaton et al. Feb 2002 B1
6383163 Kelly et al. May 2002 B1
6391294 Dettmar et al. May 2002 B1
6398761 Bills et al. Jun 2002 B1
6398767 Fleischmann Jun 2002 B1
6402724 Smith et al. Jun 2002 B1
6440167 Shimizu Aug 2002 B2
6447802 Sessions et al. Sep 2002 B2
6450773 Upton Sep 2002 B1
6458109 Henley et al. Oct 2002 B1
6465708 Augustine Oct 2002 B1
6468295 Augustine et al. Oct 2002 B2
6471685 Johnson Oct 2002 B1
6471982 Lydon et al. Oct 2002 B1
6481986 Silver et al. Nov 2002 B1
6482491 Samuelsen et al. Nov 2002 B1
6486285 Fujita Nov 2002 B2
6491684 Joshi et al. Dec 2002 B1
6495127 Wallace et al. Dec 2002 B1
6500112 Khouri Dec 2002 B1
6509031 Miller et al. Jan 2003 B1
6521251 Askill et al. Feb 2003 B2
6547467 Quintero Apr 2003 B2
6547756 Greter et al. Apr 2003 B1
6553998 Heaton Apr 2003 B2
6575940 Levinson et al. Jun 2003 B1
6580012 Augustine et al. Jun 2003 B1
6596704 Court et al. Jul 2003 B1
6599262 Masini Jul 2003 B1
6626891 Ohmstede Sep 2003 B2
6627216 Brandt et al. Sep 2003 B2
6629774 Gruendeman Oct 2003 B1
6638270 Johnson Oct 2003 B2
6648862 Watson Nov 2003 B2
6673028 Argenta et al. Jan 2004 B1
6676610 Morton et al. Jan 2004 B2
6676631 Greter Jan 2004 B1
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6695824 Howard et al. Feb 2004 B2
6699213 Annis et al. Mar 2004 B1
6730299 Tayot et al. May 2004 B1
6752794 Lockwood Jun 2004 B2
6755807 Risk, Jr. Jun 2004 B2
6764462 Risk, Jr. et al. Jul 2004 B2
6767334 Randolph Jul 2004 B1
6775807 Lowther et al. Aug 2004 B2
6787682 Gilman Sep 2004 B2
6790438 Constancis et al. Sep 2004 B1
6800074 Henley et al. Oct 2004 B2
6808517 Greter et al. Oct 2004 B2
6814079 Heaton et al. Nov 2004 B2
6824533 Risk, Jr. et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6856821 Johnson Feb 2005 B2
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
6960179 Gura Nov 2005 B2
6977323 Swenson Dec 2005 B1
6979324 Bybordi et al. Dec 2005 B2
6987209 Augustine et al. Jan 2006 B2
6994702 Johnson Feb 2006 B1
6997897 Silver et al. Feb 2006 B1
7004915 Boynton et al. Feb 2006 B2
7008400 Silver et al. Mar 2006 B2
7022113 Lockwood et al. Apr 2006 B2
7067709 Murata et al. Jun 2006 B2
7070584 Johnson et al. Jul 2006 B2
7077832 Fleischmann Jul 2006 B2
7087806 Scheinberg et al. Aug 2006 B2
7108683 Zamierowski Sep 2006 B2
7117869 Heaton et al. Oct 2006 B2
7118545 Boyde Oct 2006 B2
7122046 Augustine et al. Oct 2006 B2
7128735 Weston Oct 2006 B2
7129210 Lowinger et al. Oct 2006 B2
7141714 Nielsen Nov 2006 B2
7182085 Larsen et al. Feb 2007 B1
7195624 Lockwood et al. Mar 2007 B2
7214202 Vogel et al. May 2007 B1
7216651 Argenta et al. May 2007 B2
7238850 Shimanuki Jul 2007 B2
7255681 Silver et al. Aug 2007 B1
7273054 Heaton et al. Sep 2007 B2
7279612 Heaton et al. Oct 2007 B1
7303757 Schankereli et al. Dec 2007 B2
7316672 Hunt et al. Jan 2008 B1
7335809 Riesinger Feb 2008 B2
7338482 Lockwood et al. Mar 2008 B2
7361184 Joshi Apr 2008 B2
7381211 Zamierowski Jun 2008 B2
7381859 Hunt et al. Jun 2008 B2
7438705 Karpowicz et al. Oct 2008 B2
7470830 Sigurjonsson et al. Dec 2008 B2
7485112 Karpowicz et al. Feb 2009 B2
7494482 Orgill et al. Feb 2009 B2
7503910 Adahan Mar 2009 B2
7507870 Nielsen et al. Mar 2009 B2
7524286 Johnson Apr 2009 B2
7524315 Blott et al. Apr 2009 B2
7534240 Johnson May 2009 B1
7534927 Lockwood et al. May 2009 B2
7569742 Haggstrom et al. Aug 2009 B2
7601129 Aali Oct 2009 B2
7605298 Bechert et al. Oct 2009 B2
7611500 Lina et al. Nov 2009 B1
7612247 Oyaski Nov 2009 B2
7615036 Joshi et al. Nov 2009 B2
7622629 Aali Nov 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7645253 Gura et al. Jan 2010 B2
7645269 Zamierowski Jan 2010 B2
7670323 Hunt et al. Mar 2010 B2
7678090 Risk, Jr. et al. Mar 2010 B2
7699823 Haggstrom et al. Apr 2010 B2
7699830 Martin Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7717313 Criscuolo et al. May 2010 B2
7718249 Russell et al. May 2010 B2
7722582 Lina et al. May 2010 B2
7731702 Bybordi et al. Jun 2010 B2
7745681 Ferguson Jun 2010 B1
7749531 Booher Jul 2010 B2
7753894 Blott et al. Jul 2010 B2
7754936 Heaton et al. Jul 2010 B2
7754937 Boehringer et al. Jul 2010 B2
7758514 Grigoryants et al. Jul 2010 B2
7758554 Lina et al. Jul 2010 B2
7759537 Bishop et al. Jul 2010 B2
7759538 Fleischmann Jul 2010 B2
7759539 Shaw et al. Jul 2010 B2
7763000 Risk, Jr. et al. Jul 2010 B2
7763769 Johnson et al. Jul 2010 B2
7775998 Riesinger Aug 2010 B2
7776028 Miller et al. Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
7790945 Watson, Jr. Sep 2010 B1
7790946 Mulligan Sep 2010 B2
7794438 Henley et al. Sep 2010 B2
7794450 Blott et al. Sep 2010 B2
7803980 Griffiths et al. Sep 2010 B2
7811269 Boynton et al. Oct 2010 B2
7812212 Propp et al. Oct 2010 B2
7815616 Boehringer et al. Oct 2010 B2
7816577 Aali Oct 2010 B2
7825289 Vess Nov 2010 B2
7828782 Suzuki Nov 2010 B2
7838716 De Luis et al. Nov 2010 B2
7838717 Haggstrom et al. Nov 2010 B2
7846141 Weston Dec 2010 B2
7857806 Karpowicz et al. Dec 2010 B2
7858838 Holm et al. Dec 2010 B2
7862339 Mulligan Jan 2011 B2
7862831 Wang et al. Jan 2011 B2
7867206 Lockwood et al. Jan 2011 B2
7880050 Robinson et al. Feb 2011 B2
7883494 Martin Feb 2011 B2
7884258 Boehringer et al. Feb 2011 B2
7886746 Heaton et al. Feb 2011 B2
7896823 Mangrum et al. Mar 2011 B2
7896856 Petrosenko et al. Mar 2011 B2
7909805 Weston Mar 2011 B2
7910135 St. John et al. Mar 2011 B2
7910791 Coffey Mar 2011 B2
7922703 Riesinger Apr 2011 B2
7927318 Risk, Jr. et al. Apr 2011 B2
7931630 Nishtala et al. Apr 2011 B2
7951100 Hunt et al. May 2011 B2
7951124 Boehringer et al. May 2011 B2
7959624 Riesinger Jun 2011 B2
7964766 Blott et al. Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
D642594 Mattson et al. Aug 2011 S
7988680 Lockwood et al. Aug 2011 B2
7998125 Weston Aug 2011 B2
8007164 Miyano et al. Aug 2011 B2
8007257 Heaton et al. Aug 2011 B2
8007481 Schuessler et al. Aug 2011 B2
8012169 Joshi Sep 2011 B2
8021348 Risk, Jr. et al. Sep 2011 B2
8022266 Boehringer et al. Sep 2011 B2
8025650 Anderson et al. Sep 2011 B2
8034037 Adams et al. Oct 2011 B2
8034038 Biggie et al. Oct 2011 B2
8062272 Weston Nov 2011 B2
8062273 Weston Nov 2011 B2
8062331 Zamierowski Nov 2011 B2
8080702 Blott et al. Dec 2011 B2
8084663 Watson, Jr. Dec 2011 B2
8092441 Sugito Jan 2012 B2
8097272 Addison Jan 2012 B2
8100887 Weston et al. Jan 2012 B2
8105295 Blott et al. Jan 2012 B2
8118794 Weston Feb 2012 B2
8119160 Looney et al. Feb 2012 B2
8128615 Blott et al. Mar 2012 B2
8133211 Cavanaugh, II et al. Mar 2012 B2
8147468 Barta et al. Apr 2012 B2
8152785 Vitaris Apr 2012 B2
8158844 McNeil Apr 2012 B2
8162907 Heagle Apr 2012 B2
8162909 Blott et al. Apr 2012 B2
8168848 Lockwood et al. May 2012 B2
8188331 Barta et al. May 2012 B2
8192409 Hardman et al. Jun 2012 B2
8202261 Kazala, Jr. et al. Jun 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8211071 Mormino et al. Jul 2012 B2
8215929 Shen et al. Jul 2012 B2
8226942 Charier et al. Jul 2012 B2
8235955 Blott et al. Aug 2012 B2
8235972 Adahan Aug 2012 B2
8241261 Randolph et al. Aug 2012 B2
8246606 Stevenson et al. Aug 2012 B2
8251979 Malhi Aug 2012 B2
8257326 Vitaris Sep 2012 B2
8257327 Blott et al. Sep 2012 B2
8257328 Augustine et al. Sep 2012 B2
8267908 Coulthard Sep 2012 B2
8273368 Ambrosio et al. Sep 2012 B2
8282611 Weston Oct 2012 B2
8294586 Pidgeon et al. Oct 2012 B2
8303552 Weston Nov 2012 B2
8308714 Weston et al. Nov 2012 B2
8317774 Adahan Nov 2012 B2
8323264 Weston et al. Dec 2012 B2
8338402 Fry et al. Dec 2012 B2
8348910 Blott et al. Jan 2013 B2
8372049 Jaeb et al. Feb 2013 B2
8372050 Jaeb et al. Feb 2013 B2
8376972 Fleischmann Feb 2013 B2
8382731 Johannison Feb 2013 B2
8398614 Blott et al. Mar 2013 B2
8399730 Kazala, Jr. et al. Mar 2013 B2
8404921 Lee et al. Mar 2013 B2
D679819 Peron Apr 2013 S
D679820 Peron Apr 2013 S
8410189 Carnahan et al. Apr 2013 B2
8425478 Olson Apr 2013 B2
8444612 Patel et al. May 2013 B2
8449509 Weston May 2013 B2
8460225 Wickstrom Jun 2013 B2
8460255 Joshi et al. Jun 2013 B2
8494349 Gordon Jul 2013 B2
8506554 Adahan Aug 2013 B2
8513481 Gergely et al. Aug 2013 B2
8535283 Heaton et al. Sep 2013 B2
8535296 Blott et al. Sep 2013 B2
8545466 Andresen et al. Oct 2013 B2
8556871 Mormino et al. Oct 2013 B2
8569566 Blott et al. Oct 2013 B2
8628505 Weston Jan 2014 B2
8641691 Fink et al. Feb 2014 B2
8663198 Buan et al. Mar 2014 B2
8679079 Heaton et al. Mar 2014 B2
8708998 Weston et al. Apr 2014 B2
8715256 Greener May 2014 B2
8721606 Simmons et al. May 2014 B2
8728044 Coulthard et al. May 2014 B2
8753670 Delmotte Jun 2014 B2
8764732 Hartwell Jul 2014 B2
8784393 Weston et al. Jul 2014 B2
8795243 Weston Aug 2014 B2
8795244 Randolph et al. Aug 2014 B2
8795635 Tamarkin et al. Aug 2014 B2
8795713 Makower et al. Aug 2014 B2
8795800 Evans Aug 2014 B2
8808274 Hartwell Aug 2014 B2
8829263 Haggstrom et al. Sep 2014 B2
8834451 Blott et al. Sep 2014 B2
8834452 Hudspeth et al. Sep 2014 B2
8843327 Vernon-Harcourt et al. Sep 2014 B2
8864748 Coulthard et al. Oct 2014 B2
8911681 Song et al. Dec 2014 B2
8926592 Blott et al. Jan 2015 B2
8956336 Haggstrom et al. Feb 2015 B2
8968773 Thomas et al. Mar 2015 B2
9012714 Fleischmann Apr 2015 B2
9028872 Gaserod et al. May 2015 B2
9033942 Vess May 2015 B2
9044579 Blott et al. Jun 2015 B2
9061095 Adie et al. Jun 2015 B2
9127665 Locke et al. Sep 2015 B2
9168180 Ha et al. Oct 2015 B2
9168330 Joshi et al. Oct 2015 B2
9199012 Vitaris et al. Dec 2015 B2
9220822 Hartwell Dec 2015 B2
9302033 Riesinger Apr 2016 B2
9375353 Vitaris et al. Jun 2016 B2
9375521 Hudspeth et al. Jun 2016 B2
9381283 Adams et al. Jul 2016 B2
9414968 Heagle Aug 2016 B2
9421309 Robinson et al. Aug 2016 B2
9446178 Blott et al. Sep 2016 B2
9452248 Blott et al. Sep 2016 B2
9962474 Greener May 2018 B2
11045598 Greener Jun 2021 B2
20010004082 Keller et al. Jun 2001 A1
20010029956 Argenta Oct 2001 A1
20010031911 Khouri Oct 2001 A1
20010034499 Sessions et al. Oct 2001 A1
20010043913 Spaans et al. Nov 2001 A1
20010043943 Coffey Nov 2001 A1
20020002209 Mork Jan 2002 A1
20020026133 Augustine et al. Feb 2002 A1
20020038826 Hurray et al. Apr 2002 A1
20020068913 Fleischmann Jun 2002 A1
20020082567 Lockwood et al. Jun 2002 A1
20020115952 Johnson Aug 2002 A1
20020122771 Holland et al. Sep 2002 A1
20020143286 Tumey Oct 2002 A1
20020145007 Sawhney et al. Oct 2002 A1
20020161317 Risk et al. Oct 2002 A1
20020183702 Henley et al. Dec 2002 A1
20020187182 Kramer et al. Dec 2002 A1
20020198490 Wirt et al. Dec 2002 A1
20030014025 Allen et al. Jan 2003 A1
20030021775 Freeman Jan 2003 A1
20030023286 Augustine et al. Jan 2003 A1
20030040478 Drucker et al. Feb 2003 A1
20030045825 Etheredge, III Mar 2003 A1
20030064190 Carte et al. Apr 2003 A1
20030069529 Augustine et al. Apr 2003 A1
20030069535 Shalaby Apr 2003 A1
20030069536 Greter et al. Apr 2003 A1
20030069563 Johnson Apr 2003 A1
20030125646 Whitlock Jul 2003 A1
20030125649 McIntosh et al. Jul 2003 A1
20030143189 Askill et al. Jul 2003 A1
20030144619 Augustine Jul 2003 A1
20030153860 Nielsen et al. Aug 2003 A1
20030171675 Rosenberg Sep 2003 A1
20030175798 Raees et al. Sep 2003 A1
20030183653 Bills Oct 2003 A1
20030188754 Heaton et al. Oct 2003 A1
20030208149 Coffey Nov 2003 A1
20030212357 Pace Nov 2003 A1
20030212431 Brady et al. Nov 2003 A1
20030219469 Johnson et al. Nov 2003 A1
20030225347 Argenta Dec 2003 A1
20040019342 Nagasuna et al. Jan 2004 A1
20040024351 Greter et al. Feb 2004 A1
20040033466 Shellard et al. Feb 2004 A1
20040037897 Benjamin et al. Feb 2004 A1
20040039391 Argenta et al. Feb 2004 A1
20040039415 Zamierowski Feb 2004 A1
20040049187 Burnett et al. Mar 2004 A1
20040054338 Bybordi et al. Mar 2004 A1
20040057855 Gerlach et al. Mar 2004 A1
20040064111 Lockwood et al. Apr 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040073151 Weston Apr 2004 A1
20040073152 Karason et al. Apr 2004 A1
20040122434 Argenta et al. Jun 2004 A1
20040126413 Sigurjonsson et al. Jul 2004 A1
20040127862 Bubb et al. Jul 2004 A1
20040127863 Bubb et al. Jul 2004 A1
20040167482 Watson Aug 2004 A1
20040167617 Voellmicke et al. Aug 2004 A1
20040171976 Johnson Sep 2004 A1
20040171998 Marasco, Jr. Sep 2004 A1
20040241214 Kirkwood et al. Dec 2004 A1
20040249353 Risks, Jr. et al. Dec 2004 A1
20050013957 Leschinsky Jan 2005 A1
20050020955 Sanders et al. Jan 2005 A1
20050058694 Nielsen Mar 2005 A1
20050070835 Joshi Mar 2005 A1
20050085768 Greter et al. Apr 2005 A1
20050090787 Risk, Jr. et al. Apr 2005 A1
20050131327 Lockwood et al. Jun 2005 A1
20050148913 Weston Jul 2005 A1
20050165350 Greter et al. Jul 2005 A1
20050222544 Weston Oct 2005 A1
20050228329 Boehringer et al. Oct 2005 A1
20050230422 Muller et al. Oct 2005 A1
20050245850 Freyre et al. Nov 2005 A1
20050261642 Weston Nov 2005 A1
20050283105 Heaton et al. Dec 2005 A1
20060009744 Erdman et al. Jan 2006 A1
20060029650 Coffey Feb 2006 A1
20060069365 Sperl Mar 2006 A1
20060070458 Jones et al. Apr 2006 A1
20060079599 Arthur Apr 2006 A1
20060100586 Karpowicz et al. May 2006 A1
20060149170 Boynton et al. Jul 2006 A1
20060155260 Blott Jul 2006 A1
20060173514 Biel et al. Aug 2006 A1
20060253082 McIntosh et al. Nov 2006 A1
20060273109 Keller Dec 2006 A1
20060282028 Howard et al. Dec 2006 A1
20070004896 Ito et al. Jan 2007 A1
20070005028 Risk, Jr. et al. Jan 2007 A1
20070009580 DiCosmo et al. Jan 2007 A1
20070021697 Ginther et al. Jan 2007 A1
20070032762 Vogel Feb 2007 A1
20070032778 Heaton et al. Feb 2007 A1
20070038172 Zamierowski Feb 2007 A1
20070040454 Freudenberger et al. Feb 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070141101 Nugent et al. Jun 2007 A1
20070147947 Stenton et al. Jun 2007 A1
20070164047 Reidt et al. Jul 2007 A1
20070167884 Mangrum et al. Jul 2007 A1
20070179460 Adahan Aug 2007 A1
20070185463 Mulligan Aug 2007 A1
20070203062 Ellis-Behnke et al. Aug 2007 A1
20070219513 Lina et al. Sep 2007 A1
20070219532 Karpowicz et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070255194 Gudnason Nov 2007 A1
20070260207 Ugander et al. Nov 2007 A1
20070276195 Xu et al. Nov 2007 A1
20070276309 Xu et al. Nov 2007 A1
20080004549 Anderson et al. Jan 2008 A1
20080009812 Riesinger Jan 2008 A1
20080031748 Ihle et al. Feb 2008 A1
20080033352 Annis et al. Feb 2008 A1
20080039761 Heaton et al. Feb 2008 A1
20080045887 Larsson et al. Feb 2008 A1
20080060550 MacDonald et al. Mar 2008 A1
20080071216 Locke et al. Mar 2008 A1
20080089173 Lu et al. Apr 2008 A1
20080132821 Propp et al. Jun 2008 A1
20080188820 Joshi Aug 2008 A1
20080200905 Heaton et al. Aug 2008 A1
20080206155 Tamarkin et al. Aug 2008 A1
20080208147 Argenta et al. Aug 2008 A1
20080208163 Wilkie Aug 2008 A1
20080223378 Henderson et al. Sep 2008 A1
20080234641 Locke et al. Sep 2008 A1
20080254103 Harris et al. Oct 2008 A1
20080287880 Keller Nov 2008 A1
20080294147 Radl et al. Nov 2008 A1
20080300555 Olson et al. Dec 2008 A1
20080306407 Taylor Dec 2008 A1
20080306456 Riesinger Dec 2008 A1
20080312572 Riesinger Dec 2008 A1
20080312613 Heaton et al. Dec 2008 A1
20080314929 Keller Dec 2008 A1
20090005746 Nielsen et al. Jan 2009 A1
20090020561 Keller Jan 2009 A1
20090022779 Kelly et al. Jan 2009 A1
20090030086 Eady et al. Jan 2009 A1
20090036873 Nielsen et al. Feb 2009 A1
20090054855 Blott et al. Feb 2009 A1
20090054856 Mormino et al. Feb 2009 A1
20090082740 Lockwood et al. Mar 2009 A1
20090093550 Rolfes et al. Apr 2009 A1
20090093779 Riesinger Apr 2009 A1
20090098073 MacDonald et al. Apr 2009 A1
20090125004 Shen et al. May 2009 A1
20090131888 Joshi May 2009 A1
20090131892 Karpowicz et al. May 2009 A1
20090134186 Keller May 2009 A1
20090137973 Karpowicz et al. May 2009 A1
20090157017 Ambrosio Jun 2009 A1
20090157024 Song Jun 2009 A1
20090192467 Hansen et al. Jul 2009 A1
20090196844 Choi et al. Aug 2009 A1
20090198201 Adahan Aug 2009 A1
20090204085 Biggie et al. Aug 2009 A1
20090216170 Robinson et al. Aug 2009 A1
20090216204 Bhavaraju et al. Aug 2009 A1
20090221977 Blott et al. Sep 2009 A1
20090234306 Vitaris Sep 2009 A1
20090240218 Braga et al. Sep 2009 A1
20090254053 Svensby et al. Oct 2009 A1
20090254066 Heaton et al. Oct 2009 A1
20090259203 Hu et al. Oct 2009 A1
20090264807 Haggstrom et al. Oct 2009 A1
20090270820 Johnson et al. Oct 2009 A1
20090275872 Addison et al. Nov 2009 A1
20090275922 Coulthard et al. Nov 2009 A1
20090287129 Boehringer et al. Nov 2009 A1
20090293887 Wilkes et al. Dec 2009 A1
20090299251 Buan Dec 2009 A1
20090299255 Kazala, Jr. et al. Dec 2009 A1
20090299257 Long et al. Dec 2009 A1
20090299306 Buan Dec 2009 A1
20090312723 Blott et al. Dec 2009 A1
20100004611 Aali Jan 2010 A1
20100016767 Jones et al. Jan 2010 A1
20100022972 Lina et al. Jan 2010 A1
20100030170 Keller et al. Feb 2010 A1
20100030171 Canada et al. Feb 2010 A1
20100030178 MacMeccan et al. Feb 2010 A1
20100036305 Green Feb 2010 A1
20100036334 Heagle et al. Feb 2010 A1
20100036367 Krohn Feb 2010 A1
20100069829 Hutchinson et al. Mar 2010 A1
20100069850 Fabo Mar 2010 A1
20100069858 Olson Mar 2010 A1
20100069863 Olson Mar 2010 A1
20100087767 McNeil Apr 2010 A1
20100094234 Ramella et al. Apr 2010 A1
20100106112 Vogel Apr 2010 A1
20100106117 Lockwood et al. Apr 2010 A1
20100121286 Locke et al. May 2010 A1
20100122417 Vrzalik et al. May 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100145289 Lina et al. Jun 2010 A1
20100159192 Cotton Jun 2010 A1
20100160878 Hunt et al. Jun 2010 A1
20100160879 Weston Jun 2010 A1
20100160880 Weston Jun 2010 A1
20100168633 Bougherara et al. Jul 2010 A1
20100174251 Weston Jul 2010 A1
20100210986 Sanders et al. Aug 2010 A1
20100230467 Criscuolo et al. Sep 2010 A1
20100249733 Blott et al. Sep 2010 A9
20100262090 Riesinger Oct 2010 A1
20100262091 Larsson Oct 2010 A1
20100268176 Johnson et al. Oct 2010 A1
20100280468 Haggstrom et al. Nov 2010 A1
20100286639 Scholz Nov 2010 A1
20100305490 Coulthard et al. Dec 2010 A1
20100318052 Ha Dec 2010 A1
20110004172 Eckstein et al. Jan 2011 A1
20110004173 Hu et al. Jan 2011 A1
20110009838 Greener Jan 2011 A1
20110021431 Jones et al. Jan 2011 A1
20110022013 Boynton et al. Jan 2011 A1
20110028919 Johnnison et al. Feb 2011 A1
20110028920 Johannison Feb 2011 A1
20110028921 Hartwell et al. Feb 2011 A1
20110033503 Sinko et al. Feb 2011 A1
20110034869 Greter et al. Feb 2011 A1
20110034888 Aali Feb 2011 A1
20110034894 Riesinger Feb 2011 A1
20110046585 Weston Feb 2011 A1
20110054421 Hartwell Mar 2011 A1
20110054423 Blott et al. Mar 2011 A1
20110086077 McCrea et al. Apr 2011 A1
20110092958 Jacobs Apr 2011 A1
20110105963 Hu et al. May 2011 A1
20110106030 Scholz May 2011 A1
20110112492 Bharti et al. May 2011 A1
20110118683 Weston May 2011 A1
20110125066 Robinson et al. May 2011 A1
20110130712 Topaz Jun 2011 A1
20110172615 Greener Jul 2011 A2
20110172617 Riesinger Jul 2011 A1
20110270201 Bubb et al. Nov 2011 A1
20110270202 Boehringer et al. Nov 2011 A1
20110295220 Heaton et al. Dec 2011 A1
20110313373 Riesinger Dec 2011 A1
20110313374 Lockwood et al. Dec 2011 A1
20120053538 Blott et al. Mar 2012 A1
20120109085 McNeil May 2012 A1
20120130332 Cotton et al. May 2012 A1
20130066285 Locke et al. Mar 2013 A1
20130090615 Jaeb et al. Apr 2013 A1
20130102979 Coulthard et al. Apr 2013 A1
20130138054 Fleischmann May 2013 A1
20130144230 Wu et al. Jun 2013 A1
20130150814 Buan Jun 2013 A1
20130165878 Heagle Jun 2013 A1
20130274688 Weston Oct 2013 A1
20130331822 Patel et al. Dec 2013 A1
20130338614 Heaton et al. Dec 2013 A1
20140039423 Riesinger Feb 2014 A1
20140114268 Auguste et al. Apr 2014 A1
20140155849 Heaton et al. Jun 2014 A1
20140228791 Hartwell Aug 2014 A1
20140236109 Greener Aug 2014 A1
20150032035 Banwell et al. Jan 2015 A1
20150065965 Haggstrom et al. Mar 2015 A1
20150174304 Askem et al. Jun 2015 A1
20150190286 Allen et al. Jul 2015 A1
20150209492 Blott et al. Jul 2015 A1
20150216733 Allen et al. Aug 2015 A1
20150308994 Hammond et al. Oct 2015 A1
20160051737 Joshi et al. Feb 2016 A1
20160081859 Hartwell Mar 2016 A1
20160317357 Vitaris et al. Nov 2016 A1
20170095598 Joshi et al. Apr 2017 A1
20170128642 Buan May 2017 A1
20170181896 Hartwell Jun 2017 A1
20170181897 Hartwell Jun 2017 A1
20180361039 Greener Dec 2018 A1
20210322666 Greener Oct 2021 A1
Foreign Referenced Citations (291)
Number Date Country
2198243 Feb 1996 CA
2367460 Oct 2000 CA
2390513 May 2001 CA
2121688 Jul 2001 CA
2408305 Nov 2001 CA
2458285 Mar 2003 CA
2157772 Sep 2003 CA
2186074 Dec 1994 CN
847475 Aug 1952 DE
2809828 Sep 1978 DE
3137839 Mar 1983 DE
3032092 Oct 1984 DE
3443101 May 1986 DE
3935818 May 1991 DE
4012232 Oct 1991 DE
9017289 Apr 1992 DE
19844355 Apr 2000 DE
202004017052 Jun 2005 DE
0020662 Jul 1984 EP
0257916 Mar 1988 EP
0340018 Nov 1989 EP
0353972 Feb 1990 EP
0355186 Feb 1990 EP
0521434 Jan 1993 EP
0541251 May 1993 EP
0619105 Oct 1994 EP
0858810 Aug 1998 EP
0777504 Oct 1998 EP
0888141 Jan 1999 EP
0782421 Jul 1999 EP
1007015 Jun 2000 EP
1013290 Jun 2000 EP
1029585 Aug 2000 EP
1105171 Jun 2001 EP
1105180 Jun 2001 EP
1107813 Jun 2001 EP
1030657 Oct 2001 EP
0708620 May 2003 EP
1306123 May 2003 EP
1088569 Aug 2003 EP
1411874 Apr 2004 EP
1440737 Jul 2004 EP
1452156 Sep 2004 EP
1440667 Mar 2006 EP
1284777 Apr 2006 EP
1263366 Jul 2006 EP
1726276 Nov 2006 EP
1171065 Mar 2007 EP
1880840 Jan 2008 EP
1476217 Mar 2008 EP
1897569 Mar 2008 EP
1923077 May 2008 EP
1955887 Aug 2008 EP
1985270 Oct 2008 EP
1121163 Nov 2008 EP
2079507 Jul 2009 EP
2098257 Sep 2009 EP
2111804 Oct 2009 EP
2161011 Mar 2010 EP
2185206 May 2010 EP
1718257 Aug 2010 EP
2218431 Aug 2010 EP
2326295 Jun 2011 EP
2335749 Jun 2011 EP
2349155 Aug 2011 EP
2420214 Feb 2012 EP
2021046 Mar 2012 EP
2178573 Jun 2012 EP
2462908 Jun 2012 EP
2711034 Mar 2014 EP
2305325 Apr 2014 EP
2345437 Apr 2014 EP
2648668 Jan 2015 EP
2687245 Feb 2016 EP
1163907 Oct 1958 FR
114754 Apr 1918 GB
236350 Jul 1925 GB
641061 Aug 1950 GB
1224009 Mar 1971 GB
1255395 Dec 1971 GB
1400124 Jul 1975 GB
1549756 Aug 1979 GB
2099306 Dec 1982 GB
2061732 Jun 1983 GB
2195255 Apr 1988 GB
2288734 Nov 1995 GB
2307180 May 1997 GB
2378392 Feb 2003 GB
2415908 Jan 2006 GB
2424582 Oct 2006 GB
2435419 Aug 2007 GB
2435422 Aug 2007 GB
0722820 Jul 2019 GB
S5986824 Jun 1984 JP
S5987824 Jun 1984 JP
S6180018 Apr 1986 JP
S6180018 May 1986 JP
2003165843 Jun 2003 JP
2005334188 Dec 2005 JP
1251912 Aug 1986 SU
WO-8300742 Mar 1983 WO
WO-8401904 May 1984 WO
WO-9011795 Oct 1990 WO
WO-9100718 Jan 1991 WO
WO-9209301 Jun 1992 WO
WO-9209651 Jun 1992 WO
WO-9216245 Oct 1992 WO
WO-9220299 Nov 1992 WO
WO-9306802 Apr 1993 WO
WO-9309176 May 1993 WO
WO-9420041 Sep 1994 WO
WO-9420133 Sep 1994 WO
WO-9423677 Oct 1994 WO
WO-9504511 Feb 1995 WO
WO-9514451 Jun 1995 WO
WO-9529959 Nov 1995 WO
WO-9605873 Feb 1996 WO
WO-9621410 Jul 1996 WO
WO-9640174 Dec 1996 WO
WO-9703717 Feb 1997 WO
WO-9711658 Apr 1997 WO
WO-9733922 Sep 1997 WO
WO-9742986 Nov 1997 WO
WO-9803267 Jan 1998 WO
WO-9806444 Feb 1998 WO
WO-9901173 Jan 1999 WO
WO-9917698 Apr 1999 WO
WO-9930629 Jun 1999 WO
WO-9939671 Aug 1999 WO
WO-9947097 Sep 1999 WO
WO-9965536 Dec 1999 WO
WO-0007653 Feb 2000 WO
WO-0038752 Jul 2000 WO
WO-0042957 Jul 2000 WO
WO-0050143 Aug 2000 WO
WO-0059424 Oct 2000 WO
WO-0061206 Oct 2000 WO
WO-0062827 Oct 2000 WO
WO-0064396 Nov 2000 WO
WO-0119430 Mar 2001 WO
WO-0134223 May 2001 WO
WO-0137922 May 2001 WO
WO-0162312 Aug 2001 WO
WO-0166017 Sep 2001 WO
WO-0185248 Nov 2001 WO
WO-0193793 Dec 2001 WO
WO-0202079 Jan 2002 WO
WO-0217840 Mar 2002 WO
WO-0226180 Apr 2002 WO
WO-0238096 May 2002 WO
WO-02070040 Sep 2002 WO
WO-02076379 Oct 2002 WO
WO-02083046 Oct 2002 WO
WO-02092783 Nov 2002 WO
WO-02094256 Nov 2002 WO
WO-02102864 Dec 2002 WO
WO-03045492 Jun 2003 WO
WO-03057307 Jul 2003 WO
WO-03074100 Sep 2003 WO
WO-03092620 Nov 2003 WO
WO-2004024300 Mar 2004 WO
WO-2004037334 May 2004 WO
WO-2004054632 Jul 2004 WO
WO-2004073566 Sep 2004 WO
WO-2004077387 Sep 2004 WO
WO-2005009488 Feb 2005 WO
WO-2005016179 Feb 2005 WO
WO-2005017000 Feb 2005 WO
WO-2005018695 Mar 2005 WO
WO-2005025447 Mar 2005 WO
WO-2005025666 Mar 2005 WO
WO-2005046761 May 2005 WO
WO-2005051461 Jun 2005 WO
WO-2005070480 Aug 2005 WO
WO-2005079718 Sep 2005 WO
WO-2005082435 Sep 2005 WO
WO-2005105180 Nov 2005 WO
WO-2005118011 Dec 2005 WO
WO-2005123170 Dec 2005 WO
WO-2006014534 Feb 2006 WO
WO-2006030054 Mar 2006 WO
WO-2006034128 Mar 2006 WO
WO-2006048246 May 2006 WO
WO-2006052745 May 2006 WO
WO-2006052839 May 2006 WO
WO-2006056294 Jun 2006 WO
WO-2006081403 Aug 2006 WO
WO-2006116992 Nov 2006 WO
WO-2006135506 Dec 2006 WO
WO-2007002835 Jan 2007 WO
WO-2007013064 Feb 2007 WO
WO-2007019038 Feb 2007 WO
WO-2007024230 Mar 2007 WO
WO-2007030598 Mar 2007 WO
WO-2007030599 Mar 2007 WO
WO-2007030601 Mar 2007 WO
WO-2007084792 Jul 2007 WO
WO-2007085396 Aug 2007 WO
WO-2007092405 Aug 2007 WO
WO-2007106592 Sep 2007 WO
WO-2007106594 Sep 2007 WO
WO-2007124198 Nov 2007 WO
WO-2007133618 Nov 2007 WO
WO-2008013896 Jan 2008 WO
WO-2008027449 Mar 2008 WO
WO-2008036345 Mar 2008 WO
WO-2008039223 Apr 2008 WO
WO-2008040020 Apr 2008 WO
WO-2008041926 Apr 2008 WO
WO-2008049277 May 2008 WO
WO-2008076407 Jun 2008 WO
WO-2008082444 Jul 2008 WO
WO-2008100437 Aug 2008 WO
WO-2008100440 Aug 2008 WO
WO-2008112304 Sep 2008 WO
WO-2008131895 Nov 2008 WO
WO-2008131985 Nov 2008 WO
WO-2008134544 Nov 2008 WO
WO-2008134774 Nov 2008 WO
WO-2008141228 Nov 2008 WO
WO-2008141470 Nov 2008 WO
WO-2009019227 Feb 2009 WO
WO-2009019229 Feb 2009 WO
WO-2009034322 Mar 2009 WO
WO-2009042514 Apr 2009 WO
WO-2009047524 Apr 2009 WO
WO-2009052193 Apr 2009 WO
WO-2009060327 May 2009 WO
WO-2009062327 May 2009 WO
WO-2009066104 May 2009 WO
WO-2009066105 May 2009 WO
WO-2009066106 May 2009 WO
WO-2009070905 Jun 2009 WO
WO-2009078790 Jun 2009 WO
WO-2009089390 Jul 2009 WO
WO-2009103031 Aug 2009 WO
WO-2009111657 Sep 2009 WO
WO-2009117635 Sep 2009 WO
WO-2009122989 Oct 2009 WO
WO-2009124100 Oct 2009 WO
WO-2009126833 Oct 2009 WO
WO-2009145703 Dec 2009 WO
WO-2009146441 Dec 2009 WO
WO-2009147402 Dec 2009 WO
WO-2009151380 Dec 2009 WO
WO-2009156709 Dec 2009 WO
WO-2009158124 Dec 2009 WO
WO-2009158128 Dec 2009 WO
WO-2009158130 Dec 2009 WO
WO-2010026251 Mar 2010 WO
WO-2010033271 Mar 2010 WO
WO-2010042240 Apr 2010 WO
WO-2010051068 May 2010 WO
WO-2010051418 May 2010 WO
WO-2010059849 May 2010 WO
WO-2010072309 Jul 2010 WO
WO-2010072395 Jul 2010 WO
WO-2010082872 Jul 2010 WO
WO-2010089448 Aug 2010 WO
WO-2010120776 Oct 2010 WO
WO-2010139926 Dec 2010 WO
WO-2010141271 Dec 2010 WO
WO-2010142959 Dec 2010 WO
WO-2010147592 Dec 2010 WO
WO-2011019476 Feb 2011 WO
WO-2011023275 Mar 2011 WO
WO-2011023650 Mar 2011 WO
WO-2011128651 Oct 2011 WO
WO-2011135285 Nov 2011 WO
WO-2011135286 Nov 2011 WO
WO-2011135287 Nov 2011 WO
WO-2011144888 Nov 2011 WO
WO-2012009370 Jan 2012 WO
WO-2012022484 Feb 2012 WO
WO-2012074512 Jun 2012 WO
WO-2012131237 Oct 2012 WO
WO-2012140378 Oct 2012 WO
WO-2012143665 Oct 2012 WO
WO-2012146656 Nov 2012 WO
WO-2012150235 Nov 2012 WO
WO-2012151359 Nov 2012 WO
WO-2013010907 Jan 2013 WO
WO-2013083800 Jun 2013 WO
WO-2013090810 Jun 2013 WO
WO-2013149078 Oct 2013 WO
WO-2014008348 Jan 2014 WO
WO-2014016759 Jan 2014 WO
WO-2014108476 Jul 2014 WO
WO-2014113253 Jul 2014 WO
WO-2015022334 Feb 2015 WO
WO-2015022340 Feb 2015 WO
Non-Patent Literature Citations (98)
Entry
US 6,216,701 B1, 04/2001, Heaton et al. (withdrawn)
US 6,306,115 B1, 10/2001, Kelly et al. (withdrawn)
Achterberg V., et al ., “Hydroactive Dressings and Serum Proteins: An In Vitro Study,” Journal of Wound Care, vol. 5 (2), Feb. 1996, pp. 79-82.
Advantec MFS, Inc., “Membrane Filters” (catalog), retrieved from http://www.advantecmfs.com/catalog/filt/membrane.pdf, on Jan. 29, 2016, Copyright 2001-2011, 17 pages.
Annex to the Communication, re the Opposition of European Patent No. EP2214610, dated Mar. 3, 2020, 17 pages.
Argenta L C., et al., “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience,” Annals of Plastic Surgery, vol. 38 (6), Jun. 1997, pp. 563-577.
Arnljots B., et al., “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers,” Scandinavian Journal of Plastic and Reconstructive Surgery, vol. 19, 1985, pp. 211-213.
Aubrey D.A., et al., “Treatment of the Perineal Wound after Proctectomy by Intermittent Irrigation,” Arch. Surg, vol. 119, Oct. 1984, pp. 1141-1144.
Bagautdinov N.A., “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” in Current Problems in Modern Clinical Surgery, Interdepartmental Collection, 1986, pp. 94-96.
BASF, Elastollan Physical Properties, 2020, 1 page.
Bevan D., et al., “Diverse and potent activities of HGF/SF in skin wound repair,” Journal of Pathology, vol. 203, 2004, pp. 831-838.
Biblehimer H.L., “Dealing with a Wound that Drains 1.5 Liters a Day,” RN, Aug. 1986, pp. 21-23.
Bier A., “Hyperemia as a Therapeutic Agent,” UCI CCM Library, 1905, pp. 74-85.
Bragina, I.O., et al., “Radical Phenylation of Amides of Thiocinnamic Acid,” Russian Chemical Bulletin, Dec. 31, 1983, 3 pages.
Brief Communication on Oral proceedings—Letter from the Opponent, re the Opposition of European Patent No. EP2214610, dated Feb. 26, 2021, 6 pages.
Brubacher L.L., “To Heal a Draining Wound,” RN, Mar. 1982, pp. 30-35.
Bucalo B., et al., “Inhibition of Cell Proliferation by Chronic Wound Fluid,” Wound Repair and Regeneration, Miami, Jul.-Sep. 1993, pp. 181-186.
Chariker M.E., et al., “Effective Management of Incisional and Cutaneous Fistulae with Closed Suction Wound Drainage,” Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63.
Chintamani et al., “Half Versus Full Vacuum Suction Drainage After Modified Radical Mastectomy for Breast Cancer—a Prospective Randomized Clinical Trial,” BMC Cancer, Research Article, vol. 5(11), Jan. 27, 2005, 5 pages.
Costunchenok B M., et al., “Effect of Vacuum on Surgical Purulent Wounds,” Vestnik Chirurgia, Sep. 1986, 6 pages.
Davydov Y A., et al., “Concepts for Clinical Biological Management of the Wound Process in the Treatment of Purulent Wounds Using Vacuum Therapy,” Vestnik Khirugii, Feb. 1991, pp. 15-17.
Davydov Y.A., et al., “Pathogenic Mechanisms of the Effect of Vacuum Therapy on the Course of the Wound Process,” Khirurgiya, vol. 6, Dec. 1990, pp. 42-47.
Davydov Y.A., et al., “The Bacteriological and Cytological Assessment of Vacuum Therapy of Purulent Wounds,” Vestnik Khirurgii, Oct. 1988, pp. 11-14.
Davydov Y.A., et al., “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis,” The Kremlin Papers: Perspectives in Wound Care, Vestnik Khirurgii, BlueSky Publishing, 2004, pp. 5-7.
De Lange M.Y., et al., “Vacuum-Assisted Closure: Indications and Clinical Experience,” Eur J Plast Surg (2000), vol. 23, Feb. 9, 2000, pp. 178-182.
Dilmaghani A., et al., “A Method for Closed Irrigation and Suction Therapy in Deep Wound Infections,” Journal of Bone and Joint Surgery, Mar. 1969, vol. 51-A(2), pp. 323-342.
Fleischmann W., et al., “Vacuum Sealing: Indication, Technique, And Results,” Eur J Orthop Surg Traumatol, vol. 5, 1995, pp. 37-40.
Fleischmann W., “Vakuumversiegelung zur Behandlung von Problemwunden” Wund Forum Spezial, (with English translation: Vacuum Sealing for Treatment of Problematical Wounds), IHW '94, pp. 54-55 (6 pages with English translation).
Garcia-Rinaldi R., et al., “Improving the Efficiency of Wound Drainage Catheters,” American Journal of Surgery, Sep. 1975, vol. 130, pp. 372-373.
Greer S.E., et al., “Techniques for Applying Subatmospheric Pressure Dressing to Wounds in Difficult Regions of Anatomy,” JWOCN, vol. 26(5), Sep. 1999, pp. 250-253.
Hartz R.S., et al., “Healing of the Perineal Wound,” The Archives of Surgery, Apr. 1980, vol. 115, pp. 471-474.
Health Technology Literature Review, “Vacuum Assisted Closure Therapy for Wound Care,” The Medical Advisory Secretariat, Dec. 2004, pp. 1-57.
Hersle K., et al., “Uses of Dextranomer Absorbent Pads After Cryosurgery of Cutaneous Malignancies,” The Journal of Dermatologic Surgery and Oncology, vol. 8, Jan. 1982, pp. 35-37.
Info V.A.C. User Manual, KCI on Dec. 1, 2006 in 76 pages.
International Preliminary Report on Patentability for Application No. PCT/GB2008/051088, dated May 25, 2010, 7 pages.
International Search Report for Application No. PCT/GB2008/051088, dated Mar. 4, 2009, 2 pages.
Invalidity Suit by KCI Medizinprodukte GmbH versus Kalypto Medical, Inc., concerning declaration of invalidity of the German part of the European Patent No. 2021046 (German application No. 602007021330.4) dated Mar. 11, 2015 in 66 pages. EP2021046 is related to the present application by virtue of a common priority claim to U.S. Appl. No. 11/432,855, now U.S. Pat. No. 7,615,036, and U.S. Appl. No. 11/610,458, now U.S. Pat. No. 7,779,625.
Jeter K F., et al., “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, Chapter 27, 1990, pp. 240-246.
Johnson F.E., “An Improved Technique for Skin Graft Placement using a Suction Drain, Surgery, Gynecology and Obstetrics,” Dec. 1984, pp. 584-585 (3 pages).
Kalypto Medical, “NPD 1000 Negative Pressure Wound Care System,” Clinician & Patient Instructions for Use, Feb. 2010, 36 pages.
Kalypto Medical, NPD 1000 Product Brochure (publication date unknown, believed to be Nov. 2010), 4 pages.
KCI Inc., “If It's Not V.A.C. Therapy, It's Not Negative Pressure Wound Therapy,” KCI Brochure, Jan. 2005, 5 pages.
KCI Licensing Inc, “Prevena™ Incision Management System—Clinician Guide—Instructions for Use,” 390061 Rev D, Jan. 2010, 10 pages.
KCI, “Prevena—Incision Management System Patient Guide,” Jan. 2010, 2 pages.
KCI, “V.A.C. Freedom User's Guide,” May 2002, 16 pages.
Kendall ULTEC Hydrocolloid Dressing (4x4″), Product Ordering Page, web page downloaded on Jul. 13, 2014, 1 page.
Khirugii V., “A Collection of Published Studies Complementing the Research and Innovation of Wound Care,” The Kremlin Papers, Perspectives in Wound Care, Russian Medical Journal, Blue Sky Publishing, 2004, pp. 2-17.
Kostiuchenok B.M., et al., “The Vacuum Effect in the Surgical Treatment of Purulent Wounds,” Russian Journal: Vestnik Khirurgii, Sep. 1986, pp. 18-21.
Landes R.R., et al., “An Improved Suction Device for Draining Wounds,” Arch. Surg., vol. 104, May 1972, p. 707.
Landis E.M., et al., “The Effects of Alternate Suction and Pressure on Blood Flow to the Lower Extremities,” Alternate Suction and Pressure, J Clin Invest, Sep. 1993, vol. 12 (5), pp. 925-961.
Linden, W.V.D., et al., “Randomized Trial of Drainage After Cholecystectomy: Suction Versus Static Drainage Through a Main Wound Versus a Stab Incision,” American Journal of Surgery, Feb. 1981, vol. 141, pp. 289-294.
McFarlane R.M., “The Use of Continuous Suction under Skin Flaps,” British Journal of Plastic Surgery, 1958, pp. 77-86.
McLaughlan J., et al., “Sterile Microenvironment for Postoperative Wound Care,” The Lancet, Sep. 2, 1978, pp. 503-504.
Meyer D.C., et al., “Weight-Loaded Syringes as a Simple and Cheap Alternative to Pumps for Vacuum-Enhanced Wound Healing,” Plastic and Reconstructive Surgery, Jun. 2005, vol. 115(7), pp. 2174-2176.
Mitchell R.N., et al., “Role of Stem Cells in Tissue Homeostasis,” Pocket Companion to Robbins and Cotran Pathologic Basis of Disease, 7th Edition, 2006, p. 55 (3 pages).
Morykwas M.J., et al., “Nonsurgical Modalities to Enhance Healing and Care of Soft Tissue Wounds,” Journal of the Southern Orthopaedic Association, vol. 6, No. 4, 1997, pp. 279-288.
Morykwas M.J., et al., “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals Plastic Surgery, vol. 38 (6), Jun. 1997, pp. 553-562.
Nakayama Y., et al., “A New Method for the Dressing of Free Skin Grafts,” Plastic and Reconstructive Surgery, vol. 86(6), Dec. 1990, pp. 1216-1219.
Notice of Opposition—Statement of Facts and Evidence of the European Patent No. 2214610, dated Jul. 8, 2019, 18 pages.
Nursing75., “Wound Suction: Better Drainage with Fewer Problems,” Oct. 1975, pp. 52-53.
Nursing75., “Wound Suction: Better Drainage with Fewer Problems,” vol. 5(10), Oct. 1975, pp. 52-55.
Opponent's Written Submission in Preparation for the Oral Proceedings, for the Opposition of European Patent No. 2214610, dated Sep. 25, 2020, 5 pages.
Proprietor's Written Submission in Preparation for the Oral Proceedings, for the Opposition of European Patent No. 2214610, dated Oct. 1, 2020, 20 pages.
Protz K., “Modern Wound Dressings Support the Healing Process,” Wound care: Indications and Application, Geriatrie Journal, Apr. 2005, pp. 3333-3339 (17 pages with English translation).
Ramirez O.M., et al., “Optimal Wound Healing Under Op-Site Dressing,” Ideas and Innovations, vol. 73 (3), May 9, 1983, pp. 474-475.
Ranson, J.H.C., et al., “Safer Intraperitoneal Sump Drainage,” Surgery, Gynecology & Obstetrics, Nov. 1973, vol. 137, pp. 841-842.
Reply of the Patent Proprietor to the Notice of Opposition, re the Opposition of European Patent No. 2214610, dated Dec. 3, 2019, 25 pages.
Sames C.P., “Sealing of Wounds with Vacuum Drainage”, British Medical Journal, Nov. 5, 1977, p. 1223.
Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System,” Spiral Booklet, Mar. 2011, 7 pages.
Solovev V. A, et al., “The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract—Guidelines,” USSR Ministry of Health, S. M. Kirov Gorky State Medical Institute, 1987, 19 pages.
Solovev V.A., “Treatment and Prevention of Suture Failures after Gastric Resection,” Dissertation Abstract, Gorky, 1988, 51 pages.
Stewart J., “World Wide Wounds—Next Generation of Products for Wound Management,” Nov. 2002, http://www.worldwidewounds.com/2003/aprii/Stewart/Next-Generation-Products.html,13 pages.
Summons to attend oral proceedings pursuant to Rule 115(1) EPC for Patent No. EP2214610, mailed on Feb. 19, 2021, 17 pages.
Svedman P., “A Dressing Allowing Continuous Treatment of a Biosurface,” IRCS Medical Science: Biomedical Technology; Clinical Medicine; Surgery and Transplantation, vol. 7, 1979, p. 221.
Svedman P., et al., “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation,” Annals of Plastic Surgery, vol. 17 (2), Aug. 1986, 9 pages.
Svedman P., “Irrigation Treatment of Leg Ulcers,” The Lancet, Sep. 3, 1983, pp. 532-534.
Swift S., et al., “Quorum Sensing in Aeromonas Hydrophila and Aeromonas Salmoncida: Identification of LuxRI Homologs AhyRI and AsaRI and Their Cognate N-Acylhomoserine Lactone Signal Molecules,” Journal of Bacteriology, Sep. 1997, vol. 179, No. 17, pp. 5271-5281.
Technology Watch, May 1989, 1 page.
Teder H., et al., “Continuous Wound Irrigation in the Pig,” Journal of Investigative Surgery, 1990, vol. 3, pp. 399-407.
The Free Dictionary, “Flap Valve,” Webster's Revised Unabridged Dictionary, retrieved from http://www.thefreedictionary.com/flapper+valve, published 1913 by C. & G. Merriam Co, 2 pages.
Tribble D E., “An Improved Sump Drain-Irrigation Device of Simple Construction,” Archives of Surgery, vol. 105, Sep. 1972, pp. 511-513.
Usupov Y. N., et al., “Active Wound Drainage,” Russian Journal: Vestnik Khirurgii, Apr. 1987 (p. 42-45), Perspectives in Wound Care, BlueSky Publishing, pp. 8-10.
Venturi M L., et al., “Mechanisms and Clinical Applications of the Vacuum-Assisted Closure (VAC) Device,” Am J Clin Dermatol, 2005, vol. 6, No. 3, pp. 185-194.
Viljanto J., et al., “Local Hyperalimentation of Open Wounds,” Br. J. Surg., vol. 63, 1976, pp. 427-430.
Wackenfors A., et al., “Effects of Vacuum-Assisted Closure Therapy on Inguinal Wound Edge Microvascular Blood Flow,” Wound Repair and Regeneration, vol. 12, No. 6, Nov.-Dec. 2004, pp. 600-606.
Webb L X., “New Techniques in Wound Management: Vacuum-Assisted Wound Closure,” Journal of the American Academy of Orthopaedic Surgeons, vol. 10, No. 5, Sep./Oct. 2002, pp. 303-311.
Westaby S., et al., “A Wound Irrigation Device,” The Lancet, Sep. 2, 1978, pp. 503-504.
Wooding-Scott M., et al., “No Wound is Too Big for Resourceful Nurses,” RN, Dec. 1988, pp. 22-25.
Wu S.H., et al., “Vacuum Therapy as an Intermediate Phase in Wound Closure: A Clinical Experience,” Eur J Plast Surg, 2000, vol. 23, pp. 174-177.
Decision revoking the European Patent (Art. 101 (3)(b) EPC) for European Patent No. 2214610, mailed on Nov. 15, 2021, 43 pages.
Forwarding of submissions to parties of a letter of the Opponent for European Patent No. 2214610, dated Jul. 19, 2022, 12 pages.
Information about the Result of Oral Proceedings, the Opposition of European Patent No. 2214610, dated Oct. 8, 2021, 7 pages.
Statement of Grounds of Appeal for the Opposition of European Patent No. 2214610, mailed on Mar. 8, 2022, 49 pages.
Written Submission by the Opponent re the Opposition Proceedings for European Patent No. 2214610, mailed on Aug. 4, 2021, 2 pages.
Written Submission by the Proprietor re the Opposition Proceedings for European Patent No. 2214610, mailed on Aug. 6, 2021, 23 pages.
3M Tegaderm, “Transparent Film Dressings,” Product Profile, filed in Opposition Proceedings for European Patent No. 2214610, mailed on Aug. 4, 2020, 8 pages.
Declaration of Chris Locke submitted in the Opposition against European Patent No. EP 2563308, dated Sep. 7, 2016, 6 pages.
Reply to Opponent's Submission dated Jul. 13, 2022, for European Patent No. 2214610, mailed on Nov. 9, 2022, 6 pages.
Related Publications (1)
Number Date Country
20210322666 A1 Oct 2021 US
Divisions (1)
Number Date Country
Parent 14254807 Apr 2014 US
Child 15973111 US
Continuations (2)
Number Date Country
Parent 15973111 May 2018 US
Child 17360893 US
Parent 12744055 US
Child 14254807 US